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reamble
ver the past decade, there has been an increasing aware-
ess that the quality of medical care delivered in the United
tates is variable. In its seminal document dedicated to
haracterizing deficiencies in delivering effective, timely,
afe, equitable, efficient, and patient-centered medical care,
he Institute of Medicine described a quality “chasm” (1).
ecognition of the magnitude of the gap between the care
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December 14/21, 2010:2147–81 Performance Measures for Adults With PADhat is delivered and the care that ought to be provided has
timulated interest in the development of measures of
uality of care and the use of such measures for the purposes
f quality improvement and accountability.
Consistent with this national focus on healthcare quality,
he American College of Cardiology Foundation (ACCF)
nd the American Heart Association (AHA) have taken a
eadership role in developing measures of the quality of care
or cardiovascular disease (CVD) in several clinical areas
Table 1). The ACCF/AHA Task Force on Performance
easures was formed in February 2000 and was charged
ith identifying the clinical topics appropriate for the
evelopment of performance measures and with assembling
riting committees composed of clinical and methodolog-
cal experts. When appropriate, these committees have
ncluded representation from other organizations involved
n the care of patients with the condition of focus. The
ommittees are informed about the methodology of perfor-
ance measure development and are instructed to construct
easures for use both prospectively and retrospectively, to
ely upon easily documented clinical criteria, and where
ppropriate, to incorporate administrative data. The data
lements required for the performance measures are linked
o existing ACCF/AHA clinical data standards to encour-
ge uniform measurements of cardiovascular care. The
riting committees are also instructed to evaluate the extent
o which existing nationally recognized performance mea-
ures conform to the attributes of performance measures
escribed by the ACCF/AHA and to strive to create
easures aligned with acceptable existing measures when
his is feasible.
The initial measure sets published by the ACCF/AHA
ocused primarily on processes of medical care, or actions
aken by healthcare providers, such as the prescription of
medication for a condition. These process measures are
ounded on the strongest recommendations contained in
able 1. ACCF/AHA Performance Measure Sets
Topic
Original
Publication Dat
hronic heart failure (2) 2005
hronic stable coronary artery disease (3) 2005
ypertension (4) 2005
T-elevation and non–ST-elevation myocardial infarction (5) 2006
ardiac rehabilitation (7) 2007
trial fibrillation (8) 2008
rimary prevention of cardiovascular disease (9) 2009
eripheral artery disease 2010*
ercutaneous coronary intervention 2011*
Planned publication date.
AACVPR indicates American Association of Cardiovascular and Pulmonary Rehabilitation; AC
ollege of Radiology; AHA, American Heart Association; NCQA, National Committee for Quality Ass
ociety for Cardiac Angiography and Interventions; SIR, Society for Interventional Radiology; SVM,he ACCF/AHA clinical practice guidelines, delineating tctions taken by clinicians in the care of patients, such as
he prescription of a particular drug for a specific condi-
ion. Specifically, the writing committees consider as
andidates for measures those processes of care that are
ecommended by the guidelines either as Class I, which
dentifies procedures and/or treatments that should be ad-
inistered, or Class III, which identifies procedures and/or
reatments that should not be administered (Table 2). Class II
ecommendations are not considered as candidates for
erformance measures. The methodology guiding the trans-
ation of guideline recommendations into process measures
as been explicitly delineated by the ACCF/AHA, provid-
ng guidance to the writing committees (10).
Although they possess several strengths, processes of care
re limited as the sole measures of quality. Thus, current
CCF/AHA Performance Measures writing committees
re instructed to consider measures of structures of care,
utcomes, and efficiency as complements to process mea-
ures. In developing such measures, the committees are
uided by methodology established by the ACCF/AHA
11). Although implementation of measures of outcomes
nd efficiency is currently not as well established as that of
rocess measures, it is expected that such measures will
ecome more pervasive over time.
Although the focus of the performance measures writ-
ng committees is on measures intended for quality
mprovement efforts, other organizations may use these
easures for external review or public reporting of
rovider performance. Therefore, it is within the scope of
he writing committee’s task to comment, when appro-
riate, on the strengths and limitations of such external
eporting for a particular CVD state or patient popula-
ion. Thus, the metrics contained within this document
re categorized as either performance measures or test
easures. Performance measures are those metrics that
Partnering Organizations Status
CC/AHA—inpatient measures Currently undergoing update
CC/AHA/PCPI—outpatient measures Currently undergoing update
CC/AHA/PCPI Currently undergoing update
CC/AHA/PCPI Currently undergoing update
CC/AHA Updated 2008 (6)
ACVPR/ACC/AHA Updated 2010 (referral measures
only) (7a)
CC/AHA/PCPI
CCF/AHA
CCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS
CCF/AHA/SCAI/PCPI/NCQA Under development
rican College of Cardiology; ACCF, American College of Cardiology Foundation; ACR, American
; PCPI, American Medical Association–Physician Consortium for Performance Improvement; SCAI,
for Vascular Medicine; SVN, Society for Vascular Nursing; and SVS, Society for Vascular Surgery.e
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est measures are those appropriate for the purposes of
uality improvement but not for external reporting until
urther validation and testing are performed.
All measures have limitations and pose challenges to
mplementation that could result in unintended conse-
uences when used for accountability. The implementa-
ion of measures for purposes other than quality improve-
ent requires field testing to address issues related but
ot limited to sample size, frequency of use of an
ntervention, comparability, and audit requirements. The
anner in which these issues are addressed is dependent
n several factors, including the method of data collec-
ion, performance attribution, baseline performance rates,
ncentives, and public reporting methods. The ACCF/
HA encourages those interested in implementing these
easures for purposes beyond quality improvement to
able 2. Applying Classification of Recommendations and Leve
Data available from clinical trials or registries about the usefulness/efficacy in different subpop
ailure, and prior aspirin use. A recommendation with Level of Evidence B or C does not imply th
end themselves to clinical trials. Even though randomized trials are not available, there may be
ffectiveness recommendations (Class I and IIa; Level of Evidence: A and B only), studies that s
eing evaluated.ork with the ACCF/AHA to consider these complexssues in pilot implementation projects, to assess limita-
ions and confounding factors, and to guide refinements
f the measures to enhance their utility for these addi-
ional purposes.
By facilitating measurements of cardiovascular healthcare
uality, ACCF/AHA performance measurement sets may
erve as vehicles to accelerate appropriate translation of
cientific evidence into clinical practice. These documents
re intended to provide practitioners and institutions that
eliver care with tools to measure the quality of their care
nd identify opportunities for improvement. It is our hope
hat application of these performance measures will provide
mechanism through which the quality of medical care can
e measured and improved.
Frederick A. Masoudi, MD, MSPH, FACC, FAHA
vidence
, such as gender, age, history of diabetes, history of prior myocardial infarction, history of heart
ecommendation is weak. Many important clinical questions addressed in the guidelines do not
clear clinical consensus that a particular test or therapy is useful or effective. †For comparative
the use of comparator verbs should involve direct comparisons of the treatments or strategiesl of E
ulations
at the r
a veryChair, ACCF/AHA Task Force on Performance Measures
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December 14/21, 2010:2147–81 Performance Measures for Adults With PAD. Introduction
he ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS Pe-
ipheral Artery Disease Performance Measures Writing
ommittee was charged to develop performance measures
or peripheral artery disease (PAD). These performance
easures address lower extremity and abdominal aortic
isease, as covered by the ACC/AHA 2005 Guidelines for
he Management of Patients With Peripheral Arterial
isease (Lower Extremity, Renal, Mesenteric, and Abdom-
nal Aortic) (hereafter, “PAD guidelines”) (12). The mea-
ures are intended for adults (age 18 years) evaluated in
he outpatient setting. The writing committee acknowl-
dges that the field is rapidly evolving due to the contribu-
ions of observational research, registries, and clinical trials.
ence, modifications to these performance measures for
AD will be necessary as the field advances. In addition,
here has been a recent change in the nomenclature for
ascular diseases (13). The term atherosclerotic vascular
isease refers to disease of the arteries (other than the
oronary arteries) caused by atherosclerosis (14). We have
ncorporated this new terminology into this document
here it is feasible to do so.
.1. Scope of the Problem
he PAD guidelines (12) state that:
the term “peripheral arterial disease” includes a diverse
group of disorders that lead to progressive stenosis or
occlusion, or aneurysmal dilation, of the aorta and its
noncoronary branch arteries, including the carotid, upper
extremity, visceral, and lower extremity arterial branches.
Peripheral arterial disease is the preferred clinical term
that should be used to denote stenotic, occlusive, and
aneurysmal diseases of the aorta and its branch arteries,
exclusive of the coronary arteries (page e7).
For the purposes of these performance measures, the term
eripheral artery disease in the title is used to denote
therosclerotic stenosis or occlusion of the aorta and arteries
upplying the lower extremities and abdominal aortic aneu-
ysms (AAAs) (13,14).
PAD is a marker of systemic atherosclerosis. It has been
stimated that approximately 8 million persons in the
nited States are afflicted with PAD (15). The prevalence
f PAD is approximately 12% of the adult population, with
en being affected slightly more than women (16,17).
owever, this percentage is age dependent. Almost 20% of
dults over the age of 70 years have PAD (18). Findings
rom a national cross-sectional survey of PARTNERS
PAD Awareness, Risk, and Treatment: New Resources for
urvival) found that PAD afflicts 29% of patients who are
ge 70 years, age 50 to 69 years with at least a 10–pack-
er-year history of smoking, or age 50 to 69 years with a
istory of diabetes (19). Despite the strikingly high preva-ence of PAD, this disease is underdiagnosed because it rften presents with atypical symptoms or no ischemic
ymptoms related to the legs at all. More than 70% of
rimary care providers in the PARTNERS study whose
atients were screened were unaware of the presence of
AD in those with the disease (19).
The clinical presentation of PAD may vary from no
ymptoms to intermittent claudication, atypical leg pain,
est pain, ischemic ulcers, or gangrene. Claudication is the
ypical symptomatic expression of PAD. However, asymp-
omatic disease may occur in up to 50% of all patients with
AD (12). The Walking and Leg Circulation Study eval-
ated the symptoms in patients with PAD. Of the 460
atients with PAD, 19.8% had no exertional leg pain, 28.5%
ad atypical leg pain, 32.6% had classic intermittent clau-
ication, and 19.1% had pain at rest (20). The results of
hese and other studies make it readily apparent that more
atients with PAD are asymptomatic or have atypical leg
ymptoms than have classic intermittent claudication.
PAD has 2 major consequences: The first is a decrease in
verall well-being and quality of life due to claudication and
typical leg pain (21–25). This often leads to patients
ecoming sedentary and limiting the amount of walking
hey do because of pain and discomfort. This may be
ssociated with depression (26). The second is a markedly
ncreased cardiovascular morbidity (myocardial infarction
nd stroke) and mortality (cardiovascular and all-cause).
reatment should be directed at each of these facets.
PAD is most often diagnosed by an ankle-brachial index
ABI) 0.9. A low ABI is an independent predictor of
ncreased mortality (27–32). In the Framingham Study,
ortality in patients with intermittent claudication was 2–3
imes higher than in age- and sex-matched control patients,
ith 75% of PAD patients dying from cardiovascular
vents. In a 15-year review of patients with claudication,
ver 66% of mortality was attributable to CVD (17). In a
0-year prospective study by Criqui et al. (33), PAD
atients both with and without a history of CVD had
ignificantly increased risk of dying from cardiovascular and
oronary heart disease compared with age-matched control
atients. The all-cause mortality was 3.1 times greater and
he CVD mortality was 5.9 times greater in patients with
AD compared with patients without PAD. The risk of
ardiovascular events has been found to be similar between
AD patients with claudication and PAD patients without
ymptoms (34). The extremely high morbidity and mortal-
ty in the PAD population is due to myocardial infarction
nd stroke (35,36). Both the Edinburgh Artery Study and
he ARIC (Atherosclerosis Risk in Communities) study
orrelated an increased risk of stroke and transient ischemic
ttack with increased PAD severity (34,37). The combina-
ion of known coronary or cerebrovascular disease with
AD has been shown to increase mortality risk. The BARI
Bypass Angioplasty Revascularization Investigation) trial
emonstrated that patients with multivessel coronary artery
isease (CAD) and PAD had a 4.9 times greater relative
isk of death compared with those individuals without PAD
(
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rospective trials involving 19,867 patients undergoing per-
utaneous coronary intervention, the 1-year mortality was
% in patients with PAD and coronary disease compared
ith 2.1% in patients with coronary disease alone (p0.001)
39).
Despite the overwhelming evidence that patients with
AD are at a markedly increased risk of myocardial infarc-
ion, stroke, and death, these patients are often under-
reated, in that they do not receive antiplatelet therapy or
tatins with the same frequency as do patients with coronary
rtery disease (19).
Thus, these PAD performance measures are directed at
trategies to improve diagnosis and treatment of patients
ith PAD with an overall goal of improving patients’
alking distance and speed, improving their quality of life,
nd decreasing cardiovascular event rates.
.2. Structure and Membership of the
riting Committee
he members of the writing committee included experi-
nced clinicians and specialists in vascular medicine, cardi-
logy, vascular surgery, exercise physiology, vascular and
nterventional radiology, interventional cardiology, endocri-
ology, and epidemiology. The writing committee also
ncluded representatives from the American Association of
ardiovascular and Pulmonary Rehabilitation (AACVPR);
he American College of Physicians (ACP); the American
ollege of Radiology (ACR); the American Diabetes As-
ociation (ADA); the National Heart, Lung, and Blood
nstitute (NHLBI); the PAD Coalition; the Society for
therosclerosis Imaging and Prevention (SAIP); the Soci-
ty for Cardiac Angiography and Interventions (SCAI); the
ociety of Cardiovascular Computed Tomography
SCCT); the Society for Cardiovascular Magnetic Reso-
ance (SCMR); the Society for Interventional Radiology
SIR); the Society for Vascular Medicine (SVM); the
ociety for Vascular Nursing (SVN); and the Society for
ascular Surgery (SVS).
.3. Disclosure of Relationships With Industry
he work of the writing committee was supported exclu-
ively by the ACCF and AHA. Committee members
olunteered their time, and there was no commercial sup-
ort for the development of these performance measures.
eetings of the writing committee were confidential and
ttended only by committee members and staff. Writing
ommittee members were required to disclose in writing all
nancial relationships with industry relevant to this topic
ccording to standard ACCF and AHA reporting policies
nd verbally acknowledged these relationships to the other
embers at each meeting (see Appendix A). A confidential
nal vote was conducted on each measure proposed for
nclusion in this set. Committee members with relationships
elevant to a specific measure did not participate in the
oting regarding that measure but were allowed to partici- sate in the discussion after disclosing the relationship. In
ddition, Appendix B includes relevant relationships with
ndustry information for all peer reviewers of this document.
.4. Review and Endorsement
etween July 20, 2009, and August 18, 2009, this perfor-
ance measure document underwent a 30-day public com-
ent period, during which ACCF and AHA members and
ther health professionals had an opportunity to review and
omment on the text in advance of its final approval and
ublication. Sixteen public responses were received.
The official peer and content review of the document was
onducted simultaneously with the 30-day public comment
eriod, with 2 peer reviewers nominated by the ACCF, 2
ominated by the AHA, and 2 peer reviewers nominated by
ach of the other partnering organizations (ACR, SCAI,
IR, SVM, SVN, and SVS) and by each collaborating
rganization (AACVPR, ADA, PAD Coalition, SAIP,
CCT, and SCMR). Additional comments were sought
rom clinical content experts and performance measurement
xperts, and 8 individual content reviewer responses were
eceived. All peer and content reviewer relationships with
ndustry information was collected and distributed to the
riting committee and is published in this document. (See
ppendix B for details.)
The ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS
010 Clinical Performance Measures for Adults With
eripheral Artery Disease was adopted by the respective
oards of Directors of the ACCF and AHA in August
010. These measures will be reviewed for currency once
nnually and updated as needed. They should be considered
alid until either updated or rescinded by the ACCF/AHA
ask Force on Performance Measures.
. Methodology
he development of performance systems involves identifi-
ation of a set of measures targeting a specific patient
opulation observed over a particular time period. To
chieve this goal, the ACCF/AHA Task Force on Perfor-
ance Measures has outlined 5 mandatory sequential steps.
ections 2.1 through 2.5 outline how the writing committee
ddressed these elements.
.1. Target Population and Care Period
he target population consists of patients age 18 years.
he writing committee developed exclusion criteria specific
o each measure to further specify the target population.
.2. Dimensions of Care
iven the multiple potential domains of treatment that can
e measured, the writing committee identified the relevant
imensions of care that should be evaluated. We placed each
otential performance measure into the relevant dimension
f care categories. Performance measures and test measures
elected for inclusion in the final set and their dimensions of
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December 14/21, 2010:2147–81 Performance Measures for Adults With PADare are summarized in Table 3. Appendix C provides the
etailed specifications for each measure.
Although the writing committee considered a number of
dditional measures that focus on equally important aspects
f care, length and complexity considerations did not allow
heir inclusion in the set. Some of the reasons for this are
iscussed later in this paper.
.3. Literature Review
he writing committee used the PAD guidelines as the
rimary source for deriving these measures (12). In addition,
he writing committee also reviewed guidelines in “Trans-
tlantic Inter-Societal Consensus for the Management of
eripheral Arterial Disease (TASC II)” (40) and the
AACVPR/ACC/AHA 2007 Performance Measures on
ardiac Rehabilitation for Referral to and Delivery of
ardiac Rehabilitation/Secondary Prevention Services” (7).
.4. Definition of Potential Measures
xplicit criteria exist for the development of performance
easures that accurately reflect quality of care. These
riteria include: 1) defining the numerators and denomina-
ors of potential measures, and 2) evaluating their applica-
ility, interpretability, and feasibility. To select measures for
nclusion in the performance measurement set, the writing
ommittee prioritized the recommendations from the PAD
uidelines (12).
.5. Selection of Measures for Inclusion in the
erformance Measure Set
rom analysis of these recommendations, the writing com-
ittee identified potential measures relevant to adults with
AD and then independently evaluated their potential for
se as performance measures using 9 exclusion criteria
dapted from the ACCF/AHA Attributes of Performance
able 3. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS PAD Per
Measure Name Risk Assessment Dia
. Ankle brachial index ✓
. Cholesterol-lowering medications (statin)
. Smoking cessation
. Antiplatelet therapy
. Supervised exercise
. Lower extremity vein bypass graft surveillance
. Monitoring of abdominal aortic aneurysms
-1. Vascular review of systems for lower
extremity PAD*
✓
-2. PAD “at risk” population pulse examination* ✓
Test measure (T-1 and T-2): This measure has been designated for use in internal quality improve
r public reporting programs).
ACCF indicates American College of Cardiology Foundation; ACR, American College of Radiology;
nd Interventions; SIR, Society of Interventional Radiology; SVM, Society for Vascular Medicine;easures (Table 4) and the Performance Measure Survey Aorm and Exclusion Criteria Definitions (Appendix D).
ember ratings of all the potential measures were collated
nd discussed by the full committee so that members could
each consensus about which measures should advance for
nclusion in the final measure set. There were 37 potential
easures initially advanced for full specification to assess
heir suitability as performance measures. Through an
terative process of repeated surveys within the writing
ommittee, these potential measures were eventually re-
uced to 7 final performance measures and 2 test measures.
fter additional discussion and refinement of measure
pecifications, the writing committee conducted a confiden-
ial vote on whether to include each measure and whether to
esignate any of the measures as test measures in the final
et. Writing committee members were required to recuse
hemselves from voting on any measures for which they had
ignificant relevant relationships with industry.
nce Measurement Set: Dimension of Care Measures Matrix
ics
Patient
Education Treatment
Self-Management/
Compliance
Monitoring of
Disease Status
✓
✓ ✓ ✓
✓
✓ ✓ ✓ ✓
✓
✓
rograms only. It is not appropriate for any other use (e.g., pay for performance, physician ranking,
merican Heart Association; PAD, peripheral artery disease; SCAI, Society for Cardiac Angiography
ociety of Vascular Nursing; and SVS, Society for Vascular Surgery.
able 4. ACCF/AHA Attributes of Performance Measures
Consideration Attribute
seful in improving
patient outcomes
Evidence-based
Interpretable
Actionable
easure design Denominator precisely defined
Numerator precisely defined
Validity type
● Face
● Content
● Construct
Reliability
easure implementation Feasibility
● Reasonable effort
● Reasonable cost
● Reasonable time period for collection
verall assessment Overall assessment of measure for inclusion
in measurement setforma
gnost
✓
✓
✓
✓
ment pdapted from Normand et al. (41).
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Performance Measures for Adults With PAD December 14/21, 2010:2147–81. Peripheral Artery Disease
erformance Measures
.1. Definition of Peripheral Artery Disease and
bdominal Aortic Aneurysm
therosclerotic vascular disease encompasses a range of
oncoronary arterial syndromes that are caused by the
ltered structure and function of the arteries that supply the
rain, visceral organs, and the limbs. Numerous pathophys-
ologic processes can contribute to the creation of stenosis or
neurysms of the noncoronary arterial circulation, but ath-
rosclerosis remains the most common disease process
ffecting the aorta and its branch arteries.
.2. Brief Summary of the Measurement Set
able 5 summarizes the ACCF/AHA/ACR/SCAI/SIR/
VM/SVN/SVS PAD Performance Measurement Set—
hose measures with the highest level of evidence and
upport among the writing committee members. Appendix
provides the detailed specifications for each performance
easure, including the numerator, denominator, period of
ssessment, method of reporting, sources of data, rationale,
linical recommendations, recommended level of attribution
nd/or aggregation, and challenges to implementation.
.3. Data Collection
hese performance measures for PAD are ideally intended for
rospective use to enhance the quality improvement process but
ay also be applied retrospectively. We recommend use of a data
able 5. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS PAD Per
Measure Name
erformance Measures
1. ABI Measurement of ABI
2. Cholesterol-Lowering Medications (Statin) Drug therapy for lowe
patients with PAD
3. Smoking Cessation Smoking-cessation in
with PAD
4. Antiplatelet Therapy Antiplatelet therapy t
stroke, or vascular
symptomatic PAD
5. Supervised Exercise Supervised exercise t
claudication
6. Lower Extremity Vein Bypass Graft Surveillance ABI and Duplex ultras
7. Monitoring of Abdominal Aortic Aneurysms Monitoring of asympt
between 4.0 and 5
est Measures
T-1. Vascular Review of Systems for
Lower Extremity PAD*
Medical or personal h
claudication or isch
in patients at risk f
T-2. PAD “At Risk” Population Pulse Examination* Measurement of puls
at risk for PAD
Test measure (T-1 and T-2): This measure has been designated for use in internal quality improve
r public reporting programs).
ABI indicates ankle brachial index; ACCF, American College of Cardiology Foundation; ACR, Am
ociety for Cardiac Angiography and Interventions; SIR, Society of Interventional Radiology; SVM,ollection instrument to aid compilation (see Appendix E). Indi-idual institutions may modify the sample instrument or develop
different tool based on local practice and standards.
.4. Exclusion Criteria and Challenges
o Implementation
he writing committee added exclusion criteria, recognizing
hat there are justifiable reasons for not meeting the perfor-
ance measures. These reasons should be recorded on the data
ollection form. Documentation of such factors should be
ncouraged because this will provide data for future research
nd facilitate in-depth quality improvement in situations in
hich there are apparent outliers with respect to the number of
atients with medical or patient-centered reasons for exclusion.
Challenges to implementation of the measures are dis-
ussed, where applicable. In general, the initial challenge
acing any measurement effort is inadequate documentation.
iscussion of these challenges is not an argument against
ny individual measure. Rather, it is a cautionary note that
raws attention to areas where additional research may
nhance the value of the measures.
. Discussion
he performance measures that were chosen fulfilled the
riteria, as outlined in Table 4:
. They are useful in improving patient outcomes and are
based on Class I evidence: interpretable and actionable.
. The measure design is precisely defined and valid in face,
nce Measurement Set
escription Attribution
ients at risk for PAD All clinicians managing patients with
cardiovascular disease
w-density lipoprotein cholesterol in All primary care and cardiovascular
medicine physicians
tion for active smoking in patients All clinicians managing patients with
cardiovascular disease
ce the risk of myocardial infarction,
in patients with a history of
All clinicians managing patients with
cardiovascular disease
for patients with intermittent All clinicians managing patients with
cardiovascular disease
of lower extremity vein bypass site Vascular specialists only
c abdominal aortic aneurysms
in diameter
All clinicians managing patients with
cardiovascular disease
of walking impairment,
rest pain, and nonhealing wounds
er extremity PAD
All clinicians managing patients with
cardiovascular disease
he lower extremities in patients All clinicians managing patients with
cardiovascular disease
rograms only. It is not appropriate for any other use (e.g., pay for performance, physician ranking,
College of Radiology; AHA, American Heart Association; PAD, peripheral arterial disease; SCAI,
for Vascular Medicine; SVN, Society of Vascular Nursing; and SVS, Society for Vascular Surgery.forma
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December 14/21, 2010:2147–81 Performance Measures for Adults With PAD. The measure can be implemented with reasonable effort
and cost and in a reasonable time period.
The writing committee examined all Class I and Class III
ecommendations from the PAD guidelines and considered
nly those guideline recommendations that could be trans-
ated into measures that met the criteria stated above. Many
otential performance measures did not meet these 3 criteria
nd thus were not included in this set of measures. Reasons
or some of these omissions are discussed in section 4.7. In
ummary, the final selection of performance measures was
ased on the evidence base for a given measure, the ease
nd/or complexity of measurement, and whether the mea-
urement was covered in previously published measurement
ets.
Assessment of care remains challenging in all areas of
edicine but is particularly so in patients with PAD. PAD
s underdiagnosed, undertreated, and poorly understood by
any practicing clinicians (19). Although the PAD guide-
ines (12) provide a good first step for many clinicians to
stablish their clinical expertise, continuing research upon
hich to base future measurement is important, and con-
inuing modification of the guidelines will be necessary to
eep up to date with current knowledge and improve patient
utcomes.
Potential performance measures for which the challenges
o implementation were considered too difficult to overcome
ere not included in this data set. In general, the require-
ents for documentation are an important challenge of any
easurement effort. The acknowledgment of these chal-
enges is not an argument against measurement. They are
isted to make the reader aware of the potential obstacles
hat may occur in any measurement set.
.1. Attribution and/or Aggregation
linical performance measures are used to assess quality of
are provided by individual physicians. Hence, caution must
e exercised if several physicians are actively involved at
nce with a particular episode of care. Given the nature and
linical course of PAD, most patients require longitudinal
ollow-up by physicians of different specialties. It is likely
hat the ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS
010 Performance Measures for Adults With Peripheral
rtery Disease will be utilized by the Centers for Medicare
nd Medicaid Services and other third-party payers to assess
ach individual physician caring for patients with PAD.
herefore, it is critical that physicians effectively document
n the patient’s medical records all clinical data necessary for
ach PAD performance measure. More important is the
eed for all clinicians who are participating in a patient’s
are to share this information consistently so that data
ollection for performance measures attributable to all
nvolved can be readily available. Such information sharing
ill also improve communication and coordination of caremong physicians caring for patients with PAD. PFor the first time in an ACCF/AHA performance
easure set, attribution and/or aggregation is listed in each
easure. Attribution indicates which clinicians and/or prac-
ices should report a given measure (i.e., all clinicians and/or
ractices managing patients with CVD versus only vascular
pecialists). The level of “aggregation” (clinician versus
ractice) will depend upon the availability of adequate
ample sizes to provide stable estimates of performance.
ealthcare providers from many different specialties (pri-
ary care, internal medicine, cardiovascular medicine, vas-
ular medicine, interventional radiology, vascular surgery,
nd endocrinology) may care for patients with PAD, yet not
ll specialists should be responsible for each performance
easure. For example, for lower extremity bypass graft
urveillance (Performance Measure 6) only vascular special-
sts should be held accountable. In addition, the writing
ommittee believes it is now beyond the scope of practice to
xpect vascular surgeons and interventional radiologists to
anage cholesterol-lowering medications (Performance
easure 2). However, vascular surgeons and interventional
adiologists should communicate with the primary care
hysician about the use of statin and antiplatelet therapy in
atients with PAD and document such communication and
edication use in the chart.
.2. Overlap With Existing National
erformance Measure Sets
ll individuals with PAD, regardless of symptom status,
BI, or efficacy of revascularization, face as high (or higher)
short-term risk of a morbid or mortal ischemic event
myocardial infarction, stroke, or death) as that suffered by
atients with any other CVD (12,42) Nevertheless, al-
hough the published peer-reviewed evidence base—as doc-
mented in the PAD guidelines (12)—unambiguously doc-
ments that impressive risk reductions are achieved by use
f proven pharmacological and lifestyle interventions, indi-
iduals with PAD in clinical practice are known to less
onsistently receive these treatments (19,43–45). Further-
ore, physicians often do not recognize the cardiovascular
isk of PAD. This is a major reason that they do not
onsistently prescribe such risk-reduction medications for
atients with PAD, as they do for individuals with coronary
rtery disease (46,47). These facts are evident even though
ther cardiovascular treatment guidelines for lipid lowering,
ypertension, and smoking have long included PAD as a
very high risk” patient cohort.
These PAD performance measures therefore provide a
ritical disease-based opportunity to improve PAD clinical
are and outcomes, which can be accomplished only if the
se of risk-reduction interventions are measured (as they
ave been for acute coronary syndromes and heart failure)
nd thus permit incremental improvement to be systemat-
cally achieved.
One measure would evaluate use of statin therapy for
owering lipoprotein cholesterol (LDL-C) in patients with
AD by measuring the fraction of eligible patients with
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Performance Measures for Adults With PAD December 14/21, 2010:2147–81AD who were prescribed a statin and whose LDL-C is
100 mg/dL. The second measure would evaluate the use
f smoking-cessation interventions for active smoking in
atients with PAD by documenting the fraction of patients
ith PAD identified as current smokers who have received
moking-cessation intervention. The third measure would
valuate use of antiplatelet therapy to reduce the risk of
yocardial infarction, stroke, or cardiovascular death in
atients with a history of symptomatic PAD. Each of these
easures should be achievable by any physician, advanced
ractice nurse, practice, or healthcare system that is dedi-
ated to improving health outcomes for individuals with
AD.
.3. Ankle Brachial Index
ndividuals with PAD are at significant risk for cardiovas-
ular ischemic events, including myocardial infarction,
troke, and death (12,48). Epidemiological studies have
hown that even asymptomatic patients suffer mortality
ates significantly higher than individuals who do not have
AD. PAD can easily be diagnosed with an ABI 0.90
12,27,29,32,33,35). The ABI is measured with a handheld
ontinuous wave Doppler ultrasound device and a blood
ressure cuff. The higher systolic pressure measured from
ither the posterior tibial or dorsalis pedis artery (in each
eg) is compared with the higher brachial artery pressure
aken from either arm. Diagnosis of PAD provides the
hysician the opportunity to initiate treatment to reduce
ardiovascular risk and therefore decrease morbidity and
ortality. This is particularly important for those individ-
als who have not previously been diagnosed with an
therosclerotic disease.
The ABI is a simple, inexpensive, noninvasive test that
an be easily performed in most clinical settings and has a
ensitivity of 79% to 95% and a specificity of 95% to 100%
12). Numerous studies have demonstrated that an abnor-
al ABI correlates with a significantly increased risk of
oronary heart disease, stroke, and cardiovascular death.
ost recently, a 2008 meta-analysis demonstrated that a
ow ABI (0.90) was associated with approximately twice
he 10-year total mortality, cardiovascular mortality, and
ajor coronary event rate compared with the overall rate in
ach Framingham Risk Score category. Including the ABI
n cardiovascular risk stratification using the Framingham
isk Score would result in reclassification of the risk
ategory and modification of treatment recommendations in
pproximately 19% of men and 36% of women (49). The
riting committee recognizes that reimbursement for the
BI in the office setting is incomplete and that requiring an
BI in persons at risk for PAD adds a burden to busy
rimary care clinicians. Despite this, the weight of the
vidence of the utility of the ABI to predict cardiovascular
orbidity and mortality and all-cause mortality and to
acilitate initiation of treatment to reduce cardiovascular
vents has led this writing committee to support the ieasurement of the ABI in patients at risk (see Perfor-
ance Measure 1 for definition of at risk) for PAD. It is the
riting committee’s belief that this measure will also be
seful in better documenting current practice patterns of
hysician office evaluation and in identifying potential
pportunities for quality improvements for patients with
AD.
.4. Antiplatelet Therapy
n the PAD guidelines (12) and the “Inter-Society
onsensus for the Management of Peripheral Arterial
isease (TASC II)” (40), antiplatelet therapy is recom-
ended for the treatment of patients with PAD. Several
ocuments in the past year have questioned the efficacy of
spirin in patients with asymptomatic PAD (50,51). The
ole of antiplatelet therapy in asymptomatic patients is
ddressed in the upcoming ACCF/AHA focused update
o the 2005 PAD guidelines; thus, we have included only
atients with a history of symptomatic PAD in this
erformance measure.
.5. Supervised Exercise
he PAD guidelines recommend supervised exercise to
reat patients with PAD who have claudication because of
ts proven efficacy and safety (12). Any performance mea-
ure that is intended to measure the “appropriateness” of
are offered to individuals with PAD and claudication
ould rightly measure the applied use of this treatment care
tandard.
Nevertheless, the writing committee is aware that, as for
any performance measures, real-world barriers exist that
imit actual use of a treatment. The efficacy and safety of
AD exercise rehabilitation for the treatment of claudica-
ion is a uniformly recommended, evidence-based, consensus-
riven therapy that has a Class I (Level of Evidence: A)
ecommendation in the 2005 PAD guidelines (12). There is
urrently incomplete reimbursement for, and therefore a
ack of broad availability of, supervised exercise programs,
hich makes this PAD performance measure difficult to
arry out. However, the data supporting the ability of
upervised exercise to increase walking capability in patients
ith claudication are so strong (52) that we feel including
his treatment modality as a performance measure may help
o move it into more general use. Another limiting factor for
he low use of exercise rehabilitation is the lack of counsel-
ng about and prescription of this therapy by many health-
are professionals. The writing committee believes that
ore patients would choose a trial of exercise, as they do in
ther rehabilitative therapies (e.g., cardiac rehabilitation,
ulmonary rehabilitation, and orthopedic rehabilitation), if
hey were made aware that this is an efficacious treatment
ption, or if they were prescribed this option, and especially
f it were carried out in a supervised setting.
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December 14/21, 2010:2147–81 Performance Measures for Adults With PADPatients with PAD should be counseled about all of their
reatment options in order to engage them fully in the
ecision-making process about their care. This counseling
nd discussion of treatment options should include use of
upervised exercise, pharmacological management, and/or
he various percutaneous or open surgical revascularization
echniques. Inasmuch as exercise rehabilitation has not to
ate been routinely recommended by clinicians, it is impos-
ible to define what percentage of patients would choose
upervised exercise as the first-line therapy if they were
ade aware of this option and if this treatment modality
ere reimbursed by third-party payers. Thus, the inclusion
f supervised exercise in the PAD performance measures
ill assure the following: 1) that this evidence-based ther-
peutic modality will be provided as a component of
nformed decision making about the various treatment
trategies for patients with PAD; 2) that data can be
ollected to evaluate current claudication treatment recom-
endation practice patterns; and 3) that these data will be
ble to be tracked over time as PAD rehabilitation pro-
rams, and possible insurance reimbursement, become more
idely available. A variety of supervised exercise protocols
ave been published (53). Practices should create individual
ptions for patients that mirror these protocols in physio-
ogic effectiveness.
It should be noted that ongoing advocacy efforts are
nder way to align future Centers for Medicare and Med-
caid Services and other health payer reimbursement to the
urrent PAD guideline evidence base and thus to include
eimbursement for PAD exercise rehabilitation programs. It
s anticipated that this essential performance measure will
ermit patients, healthcare providers, and health payers to
e able to make incremental improvements that will assure
atient access to all proven claudication therapies. Most
urrent cardiac rehabilitation programs, which are broadly
vailable, are poised to provide PAD exercise rehabilitation.
his performance measure provides data that can help
ranslate evidence-based PAD knowledge into real-world
are improvements.
.6. Test Measures
lthough it is common sense that one should obtain an
ccurate vascular history and perform a good vascular
xamination in all patients suspected of having PAD, the
riting committee chose to include measures T-1 and T-2
s test measures only. This decision was made because of the
esire to limit the number of performance measures to a
easonable number. We also believe that these measures
ould be difficult and time consuming to track and would
equire additional resources for monitoring that may not be
vailable. As test measures, their use should be for internal
uality improvement programs only. They are not appro-
riate for other uses, such as pay for performance, physician
anking, or public reporting programs. o.7. Potential Measures Considered But
ot Included in This Set
.7.1. Lower Extremity Endovascular
evascularization Surveillance
lthough there has been some controversy in the literature
here have been several good studies (Class I, Level of
vidence: A) demonstrating that surveillance for vein by-
ass is an effective way to preserve the long-term function of
he bypass and to identify and correct problems before the
ypass thromboses (54–56). There are no such studies
vailable in patients who have undergone endovascular
evascularization, yet it makes intuitive sense that if a
roblem (e.g., restenosis) can be identified, the problem may
e correctable before the artery occludes. However, the
AD guidelines gave this a Class IIa designation, thus we
ere unable to include this as a performance or test measure.
.7.2. Chronic Critical Limb Ischemia and
cute Limb Ischemia
he writing committee considered numerous potential
easures that would focus on the surgical as well as
ndovascular management of patients with chronic and
cute limb ischemia. Although the management of chronic
nd acute limb ischemia is considered extremely important
y the writing committee, specific measures were not
ncluded in this area for a variety of reasons. One of the
mportant reasons is that the goal of the writing committee
as to develop performance measures that would be relevant
o as many clinicians and as many patients as possible.
atients with chronic limb ischemia and acute limb isch-
mia needing surgical or endovascular therapy represent a
mall minority of all patients with PAD. Furthermore, the
linicians who actively manage these problems represent a
mall subset of clinicians who manage patients with PAD.
s such, the writing committee felt that the scope of any
erformance measures adopted in these areas would not be
elevant to enough patients and clinicians to justify their
nclusion.
Another reason for not including measures in these areas
s the complexity of any metrics that might be developed to
easure the performance of care. These patients present
ith very complex symptoms, with multiple comorbidities
nd significant anatomic variations, which render simple
etrics impractical. Finally, the level of evidence for estab-
ishing specific guidelines and measures in these areas is not
ufficiently rigorous to justify specific performance measures
or the management of chronic or acute limb ischemia.
.7.3. Renal and Mesenteric Artery Disease
here are no performance measures related to renal or
esenteric artery disease included in this report. While
enal artery disease is a common cardiovascular condition,
he PAD guidelines contain no Class I recommendations
elated to this disease, and no randomized controlled trials
f sufficiently high caliber exist to guide clinicians in the
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Performance Measures for Adults With PAD December 14/21, 2010:2147–81ptimal management of patients with renal artery disease.
n addition, a considerable controversy remains among
experts” as to the most effective therapy to manage this
roup of patients. Until the results of the CORAL (Car-
iovascular Outcomes in Renal Atherosclerotic Lesions)
rial (57) are reported, healthcare providers will continue to
anage this group of patients according to their interpre-
ation of the available literature.
Likewise, there is even less scientific information on
esenteric artery disease available, and thus no performance
easures were deemed appropriate for this topic.
.7.4. Exercise Treadmill Testing
xercise treadmill testing can assist clinicians in the evalu-
tion of the functional status of PAD patients. A decrease in
he postexercise ankle pressures can confirm a diagnosis of
AD in symptomatic patients who have a normal ABI at
est. In addition, exercise treadmill testing allows quantifi-
ation of a patient’s baseline and/or postprocedure func-
ional limitation or improvement.
Despite the potential benefits of this procedure, the
riting committee agreed both that this measure would be
ifficult to implement and that there were other measures
ith higher priority; thus, we decided not to include this
easure.
.7.5. Computed Tomographic Angiography and
agnetic Resonance Angiography
t has been clearly shown that computed tomographic
ngiography and magnetic resonance angiography are useful
maging strategies to delineate the anatomy and help plan
ercutaneous and surgical revascularization (12). However,
his potential performance measure did not meet the criteria
or a good performance measures as outlined in Table 4.
.7.6. Management of Hypertension and Diabetes
t is very important to control blood pressure and diabetes to
oal levels in patients with PAD. Excellent performance
easures already exist on the diagnosis and management of
ypertension and diabetes mellitus, and the reader is re-
erred to those (4,58,59).
.7.7. Screening for Abdominal Aortic Aneurysm
his was the most difficult measure to exclude. However,
he PAD guidelines assigned this only a Class IIa designa-
ion. Because only Class I designations are considered for
erformance measures, screening for abdominal aortic an-
urysm was excluded. However, the U.S. Preventive Task
orce (60) and the Societies for Vascular Medicine and
urgery (61) recommend screening for AAA in the follow-
ng patient populations:
• Men age 60 years with a history of AAA in a parent
or sibling.• Men age 65 to 75 years who have ever smoked 100
cigarettes in their lifetime.
Screening this patient population has been shown to
ecrease aneurysm-related mortality (61–64). A meta-
nalysis of 4 large randomized prospective controlled trials
65) evaluated the midterm (3.5 to 5 years) and long-term (7
o 15 years) results as related to aneurysm-related mortality
nd total mortality. Heterogeneity between the studies was
ssessed by the chi-square test. In cases of heterogeneity,
andom effect models were used. The pooled midterm
nalysis demonstrated a reduction in AAA-related mortality
odds ratio [OR]: 0.56, 95% confidence interval [CI]: 0.44
o 0.72). Overall mortality was nonsignificantly reduced
OR 0.94, 95% CI, 0.86 to 1.02). The long-term results also
howed a reduction in AAA-related mortality (OR: 0.47,
5% CI: 0.25 to 0.90) and a significant reduction in overall
ortality (OR: 0.94, 95% CI: 0.92 to 0.97). The conclusion
f this meta-analysis was that population screening for
AA reduces AAA-related and overall mortality but local
ifferences may influence the cost-effectiveness of screening.
Kim and associates (66) showed that the benefit derived
t 4 years was maintained at 7 years of follow-up, with a
elative risk reduction of aneurysm-related death of 47%.
hey also showed that there is a substantial cost-benefit to
creening, which is estimated on the basis of AAA-related
ortality as U.S. $19,500 per life-year gained. The mortal-
ty curves diverge at a constant rate after 1 year, and the area
etween the curves is greater at years 5 to 7 than years 1 to
. Thus, the cost per life-year gained decreases in the later
ears (67). Therefore, when the PAD guideline is revised, if
creening for AAA becomes a Class I recommendation,
reation of an associated performance measure will be
onsidered.
.7.8. Outcome Measures
he writing committee recognizes that the most interpret-
ble and potentially important performance measures are
utcome measures; however, there are a number of signifi-
ant limitations to their use for provider accountability or
ublic reporting (11). Outcome measures are therefore
urrently best suited for use as tools to assist providers in
nderstanding their own performance.
Krumholz et al. (6) have eloquently described the impor-
ance of assessing outcomes in addition to measuring
erformance on key processes of care, per se:
Although measures focusing on processes of care have
substantial appeal as a means of reflecting quality, such
measures assess only a small proportion of all of the care
delivered and apply to only subsets of the population
with a particular condition. Furthermore, while deter-
mining whether a particular process of care was deliv-
ered, such measures do not convey information on the
effectiveness of the process. Finally, although patients
presumably care about the processes of care that they
receive, this interest reflects an assumption that better
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these reasons, outcomes measures have been proposed as
a means of complementing process measurement as a
reflection of quality (p. 2054).
A recent multidisciplinary AHA Scientific Statement,
hich is endorsed by the ACCF, identified 7 attributes of
utcomes measures suitable for public reporting (11). These
ttributes include: 1) a clear and explicit definition of an
ppropriate patient sample; 2) clinical coherence of model
djustment variables; 3) sufficiently high-quality and timely
ata; 4) designation of an appropriate reference time before
hich covariates are derived and after which outcomes are
easured; 5) use of an appropriate outcome and a standard-
zed period of outcome assessment; 6) application of an
nalytical approach that takes into account the multilevel
rganization of data; and 7) disclosure of the methods used
o compare outcomes, including disclosure of performance
f risk-adjustment methodology in derivation and validation
amples.
While the writing committee recognizes the importance
f developing scientifically valid, effective, and useful mea-
ures of clinical outcomes for PAD, we are not yet at the
oint to do so with the data available. Outcome measure-
ents, however, should be considered in future revisions of
he PAD performance measures.
taff
merican College of Cardiology Foundation
alph G. Brindis, MD, MPH, FACC, FSCAI, President
ohn C. Lewin, MD, Chief Executive Officer
harlene May, Senior Director, Clinical Policy and
Documents
elanie Shahriary, RN, BSN, Associate Director, Perfor-
mance Measures and Data Standards
ensen S. Chiu, MHA, Specialist, Clinical Performance
Measurement
rin A. Barrett, MPS, Senior Specialist, Clinical Policy and
Documents
merican Heart Association
ancy Brown, Chief Executive Officer
ose Marie Robertson, MD, FACC, FAHA, Chief
Science Officer
ayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice
President, Office of Science Operations
wight Randle, PhD, Science and Medicine Advisor
EFERENCES
1. Institute of Medicine. Crossing the Quality Chasm: A New Health
System for the 21st Century. Washington, DC: National Academy
Press; 2001.
2. Bonow RO, Bennett S, Casey DE Jr., et al. ACC/AHA clinical
performance measures for adults with chronic heart failure: a report of
the American College of Cardiology/American Heart Association
Task Force on Performance Measures (Writing Committee to De-
velop Heart Failure Clinical Performance Measures). J Am Coll
Cardiol. 2005;46:1144–78.3. American Medical Association Physician Consortium for Performance
Improvement. Clinical performance measures: chronic stable coronary
artery disease. Available at: http://www.ama-assn.org/ama1/pub/
upload/mm/370/cadminisetjune06.pdf. Accessed January 5, 2010.
4. American Medical Association Physician Consortium for Performance
Improvement. Clinical performance measures: hypertension. Available
at : http://www.ama-assn.org/ama1/pub/upload/mm/370/
hypertension-8-05.pdf. Accessed January 5, 2010.
5. Krumholz HM, Anderson JL, Brooks NH, et al. ACC/AHA clinical
performance measures for adults with ST-elevation and non–ST-
elevation myocardial infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Performance
Measures (Writing Committee to Develop Performance Measures on
ST-Elevation and Non–ST-Elevation Myocardial Infarction). J Am
Coll Cardiol. 2006;47:236–65.
6. Krumholz HM, Anderson JL, Bachelder BL, et al. ACC/AHA 2008
performance measures for adults with ST-elevation and non–ST-
elevation myocardial infarction: a report of the American College of
Cardiology/American Heart Association Task Force on Performance
Measures (Writing Committee to Develop Performance Measures for
ST-Elevation and Non–ST-Elevation Myocardial Infarction). J Am
Coll Cardiol. 2008;52:2046–99.
7. Thomas RJ, King M, Lui K, et al. AACVPR/ACC/AHA 2007
performance measures on cardiac rehabilitation for referral to and
delivery of cardiac rehabilitation/secondary prevention services. J Am
Coll Cardiol. 2007;50:1400–33.
7a.Thomas RJ, King M, Lui K, et al. AACVPR/ACCF/AHA 2010
update: performance measures on cardiac rehabilitation for referral to
cardiac rehabilitation/secondary prevention services. J Am Coll Car-
diol. 2010;56:1159–67.
8. Estes NA III, Halperin JL, Calkins H, et al. ACC/AHA/Physician
Consortium 2008 clinical performance measures for adults with
nonvalvular atrial fibrillation or atrial flutter: a report of the American
College of Cardiology/American Heart Association Task Force on
Performance Measures and the Physician Consortium for Performance
Improvement (Writing Committee to Develop Clinical Performance
Measures for Atrial Fibrillation). J Am Coll Cardiol. 2008;51:865–84.
9. Redberg RF, Benjamin EJ, Bittner V, et al. ACCF/AHA 2009
performance measures for primary prevention of cardiovascular disease
in adults: a report of the American College of Cardiology Foundation/
American Heart Association Task Force on Performance Measures
(Writing Committee to Develop Performance Measures for Primary
Prevention of Cardiovascular Disease). J Am Coll Cardiol. 2009;54:
1364–405.
0. Spertus JA, Eagle KA, Krumholz HM, et al. American College of
Cardiology and American Heart Association methodology for the
selection and creation of performance measures for quantifying the
quality of cardiovascular care. J Am Coll Cardiol. 2005;45:1147–56.
1. Krumholz HM, Brindis RG, Brush JE, et al. Standards for statistical
models used for public reporting of health outcomes: an American
Heart Association scientific statement from the Quality of Care and
Outcomes Research Interdisciplinary Writing Group: cosponsored by
the Council on Epidemiology and Prevention and the Stroke Council.
Circulation. 2006;113:456–62.
2. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guide-
lines for the management of patients with peripheral arterial disease
(lower extremity, renal, mesenteric, and abdominal aortic): a collabo-
rative report from the American Association for Vascular Surgery/
Society for Vascular Surgery, Society for Cardiovascular Angiography
and Interventions, Society for Vascular Medicine and Biology, Society
of Interventional Radiology, and the ACC/AHA Task Force on
Practice Guidelines (Writing Committee to Develop Guidelines for
the Management of Patients With Peripheral Arterial Disease). J Am
Coll Cardiol. 2006;47:e1–192.
3. Creager MA, White CJ, Hiatt WR, et al. Atherosclerotic Peripheral
Vascular Disease Symposium II: executive summary. Circulation.
2008;118:2811–25.
4. Hiatt WR, Goldstone J, Smith SC Jr., et al. Atherosclerotic Peripheral
Vascular Disease Symposium II: nomenclature for vascular diseases.
Circulation. 2008;118:2826–9.
5. Rosamond W, Flegal K, Furie K, et al. Heart disease and stroke
statistics—2008 update: a report from the American Heart Association
Statistics Committee and Stroke Statistics Subcommittee. Circulation.
2008;117:e25–146.
11
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
3
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
6
6
6
2160 Olin et al. JACC Vol. 56, No. 25, 2010
Performance Measures for Adults With PAD December 14/21, 2010:2147–816. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of
peripheral arterial disease in a defined population. Circulation. 1985;
71:510–5.
7. Kannel WB, McGee DL. Update on some epidemiologic features of
intermittent claudiation: the Framingham Study. J Am Geriatr Soc.
1985;33:13–8.
8. Regensteiner JG, Hiatt WR. Current medical therapies for patients
with peripheral arterial disease: a critical review. Am J Med. 2002;112:
49–57.
9. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial
disease detection, awareness, and treatment in primary care. JAMA.
2001;286:1317–24.
0. McDermott MM, Greenland P, Liu K, et al. The ankle brachial index
is associated with leg function and physical activity: the Walking and
Leg Circulation Study. Ann Intern Med. 2002;136:873–83.
1. Barletta G, Perna S, Sabba C, et al. Quality of life in patients with
intermittent claudication: relationship with laboratory exercise perfor-
mance. Vasc Med. 1996;1:3–7.
2. Khaira HS, Hanger R, Shearman CP. Quality of life in patients with
intermittent claudication. Eur J Vasc Endovasc Surg. 1996;11:65–9.
3. Pell JP. Impact of intermittent claudication on quality of life. The
Scottish Vascular Audit Group. Eur J Vasc Endovasc Surg. 1995;9:
469–72.
4. Ponte E, Cattinelli S. Quality of life in a group of patients with
intermittent claudication. Angiology. 1996;47:247–51.
5. Treat-Jacobson D, Halverson S, Ratchford A, et al. A patient-derived
perspective of health-related quality-of-life in peripheral arterial dis-
ease. Journal of Nursing Scholarship. 2002;34:55–60.
6. Smolderen KG, Aquarius AE, de Vries J, et al. Depressive symptoms
in peripheral arterial disease: a follow-up study on prevalence, stability,
and risk factors. J Affect Disord. 2008;110:27–35.
7. Vogt MT, Cauley JA, Newman AB, et al. Decreased ankle/arm blood
pressure index and mortality in elderly women. JAMA. 1993;270:
465–9.
8. McKenna M, Wolfson S, Kuller L. The ratio of ankle and arm arterial
pressure as an independent predictor of mortality. Atherosclerosis.
1991;87:119–28.
9. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a
predictor of cardiovascular disease and mortality in the Cardiovascular
Health Study. Arterioscler Thromb Vasc Biol. 1999;19:538–45.
0. Criqui MH, Coughlin SS, Fronek A. Noninvasively diagnosed pe-
ripheral arterial disease as a predictor of mortality: results from a
prospective study. Circulation. 1985;72:768–73.
1. Newman AB, Tyrrell KS, Kuller LH. Mortality over four years in
SHEP participants with a low ankle-arm index. J Am Geriatr Soc.
1997;45:1472–8.
2. Resnick HE, Lindsay RS, McDermott MM, et al. Relationship of
high and low ankle brachial index to all-cause and cardiovascular
disease mortality: the Strong Heart Study. Circulation. 2004;109:
733–9.
3. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of
10 years in patients with peripheral arterial disease. N Engl J Med.
1992;326:381–6.
4. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and
cardiovascular events in symptomatic and asymptomatic peripheral
arterial disease in the general population. Int J Epidemiol. 1996;25:
1172–81.
5. Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of
peripheral arterial disease: importance of identifying the population at
risk. Vasc Med. 1997;2:221–6.
6. Ness J, Aronow WS. Prevalence of coexistence of coronary artery
disease, ischemic stroke, and peripheral arterial disease in older
persons, mean age 80 years, in an academic hospital-based geriatrics
practice. J Am Geriatr Soc. 1999;47:1255–6.
7. Zheng ZJ, Sharrett AR, Chambless LE, et al. Associations of ankle-
brachial index with clinical coronary heart disease, stroke and preclinical
carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Commu-
nities (ARIC) Study. Atherosclerosis. 1997;131:115–25.
8. Burek KA, Sutton-Tyrrell K, Brooks MM, et al. Prognostic impor-
tance of lower extremity arterial disease in patients undergoing
coronary revascularization in the Bypass Angioplasty Revascularization
Investigation (BARI). J Am Coll Cardiol. 1999;34:716–21.
9. Saw J, Bhatt DL, Moliterno DJ, et al. The influence of peripheral
arterial disease on outcomes: a pooled analysis of mortality in eightlarge randomized percutaneous coronary intervention trials. J Am Coll
Cardiol. 2006;48:1567–72.
0. Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus
for the Management of Peripheral Arterial Disease (TASC II). Eur J
Vasc Endovasc Surg. 2007;33 Suppl 1:1–75.
1. Normand SL, McNeil BJ, Peterson LE, et al. Eliciting expert opinion
using the Delphi technique: identifying performance indicators for
cardiovascular disease. Int J Qual Health Care. 1998;10:247–60.
2. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event
rates in outpatients with atherothrombosis. JAMA. 2007;297:1197–206.
3. Diehm C, Lange S, Darius H, et al. Association of low ankle brachial
index with high mortality in primary care. Eur Heart J. 2006;27:
1743–9.
4. Selvin E, Hirsch AT. Contemporary risk factor control and walking
dysfunction in individuals with peripheral arterial disease: NHANES
1999–2004. Atherosclerosis. 2008;201:425–33.
5. Feringa HH, van Waning VH, Bax JJ, et al. Cardioprotective
medication is associated with improved survival in patients with
peripheral arterial disease. J Am Coll Cardiol. 2006;47:1182–7.
6. McDermott MM, Hahn EA, Greenland P, et al. Atherosclerotic risk
factor reduction in peripheral arterial diseasea: results of a national
physician survey. J Gen Intern Med. 2002;17:895–904.
7. McDermott MM, Mandapat AL, Moates A, et al. Knowledge and
attitudes regarding cardiovascular disease risk and prevention in
patients with coronary or peripheral arterial disease. Arch Intern Med.
2003;163:2157–62.
8. Perlstein TS, Creager MA. The ankle-brachial index as a biomarker of
cardiovascular risk: it’s not just about the legs. Circulation. 2009;120:
2033–5.
9. Fowkes FG, Murray GD, Butcher I, et al. Ankle brachial index
combined with Framingham Risk Score to predict cardiovascular
events and mortality: a meta-analysis. JAMA. 2008;300:197–208.
0. Berger JS, Krantz MJ, Kittelson JM, et al. Aspirin for the prevention
of cardiovascular events in patients with peripheral artery disease: a
meta-analysis of randomized trials. JAMA. 2009;301:1909–19.
1. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of
cardiovascular events in a general population screened for a low ankle
brachial index: a randomized controlled trial. JAMA. 2010;303:841–8.
2. Hiatt WR. Medical treatment of peripheral arterial disease and
claudication. N Engl J Med. 2001;344:1608–21.
3. Stewart KJ, Hiatt WR, Regensteiner JG, et al. Exercise training for
claudication. N Engl J Med. 2002;347:1941–51.
4. Bandyk DF, Schmitt DD, Seabrook GR, et al. Monitoring functional
patency of in situ saphenous vein bypasses: the impact of a surveillance
protocol and elective revision. J Vasc Surg. 1989;9:286–96.
5. Lundell A, Lindblad B, Bergqvist D, et al. Femoropopliteal-crural
graft patency is improved by an intensive surveillance program: a
prospective randomized study. J Vasc Surg. 1995;21:26–33.
6. Davies AH, Hawdon AJ, Sydes MR, et al. Is Duplex surveillance of value
after leg vein bypass grafting? Principal results of the Vein Graft
Surveillance Randomised Trial (VGST). Circulation. 2005;112:1985–91.
7. Cooper CJ, Murphy TP, Matsumoto A, et al. Stent revascularization
for the prevention of cardiovascular and renal events among patients
with renal artery stenosis and systolic hypertension: rationale and
design of the CORAL trial. Am Heart J. 2006;152:59–66.
8. National Diabetes Quality Improvement Alliance. Performance mea-
surement set for adult diabetes. Available at: http://www-
nehc.med.navy.mil/bumed/diabetes/document%20folders/diabetes/cpg/
dqia.msrs.pdf. Accessed January 5, 2010.
9. National Quality Forum. National voluntary consensus standards for
ambulatory care: diabetes care measures. Available at: http://www.
qualityforum.org/Publications/2008/03/National_Voluntary_
Consensus_Standards_for_Ambulatory_Care%E2%80%93Part_2.aspx.
Accessed December 24, 2009.
0. Fleming C, Whitlock EP, Beil TL, et al. Screening for abdominal
aortic aneurysm: a best-evidence systematic review for the U.S.
Preventive Services Task Force. Ann Intern Med. 2005;142:203–11.
1. Kent KC, Zwolak RM, Jaff MR, et al. Screening for abdominal aortic
aneurysm: a consensus statement. J Vasc Surg. 2004;39:267–9.
2. Screening for abdominal aortic aneurysm: recommendation statement.
Ann Intern Med. 2005;142:198–202.
3. Ashton HA, Gao L, Kim LG, et al. Fifteen-year follow-up of a
randomized clinical trial of ultrasonographic screening for abdominal
aortic aneurysms. Br J Surg. 2007;94:696–701.
66
6
6
6
6
7
7
7
K
a
A
S
J
D
M
R
D
M
T
2161JACC Vol. 56, No. 25, 2010 Olin et al.
December 14/21, 2010:2147–81 Performance Measures for Adults With PAD4. Cosford PA, Leng GC. Screening for abdominal aortic aneurysm.
Cochrane Database Syst Rev. 2007;CD002945.
5. Lindholt JS, Norman P. Screening for abdominal aortic aneurysm
reduces overall mortality in men. A meta-analysis of the mid- and
long-term effects of screening for abdominal aortic aneurysms. Eur J
Vasc Endovasc Surg. 2008;36:167–71.
6. Kim LG, Scott RAP, Ashton HA, et al. A sustained mortality benefit
from screening for abdominal aortic aneurysm. Ann Intern Med.
2007;146:699–706.
7. Olin JW. Long-term outcomes and cost-effectiveness of screening for
abdominal aortic aneurysm. Nat Clin Pract Cardiovasc Med. 2007;4:
650–1.
8. MRC/BHF Heart Protection Study of cholesterol lowering with
simvastatin in 20,536 high-risk individuals: a randomised placebo-
controlled trial. Lancet. 2002;360:7–22.
9. Smith SC, Jr., Allen J, Blair SN, et al. AHA/ACC guidelines for
secondary prevention for patients with coronary and other atheroscle- srotic vascular disease: 2006 update. J Am Coll Cardiol. 2006;47:
2130–9.
0. The Vascular Disease Foundation (VDF) and the American Associ-
ation of Cardiovascular and Pulmonary Rehabilitation (AACVPR).
P.A.D. exercise training toolkit: a guide for health care professionals.
Available at: http://www.vdf.org/professionals/exercisetoolkit.php.
Accessed May 25, 2010.
1. American College of Sports Medicine. ACSM’s Guidelines for Exer-
cise Testing and Prescription. 7th ed. Baltimore, Md: Lippincott
Williams & Wilkins; 2006.
2. Penchansky R, Thomas JW. The concept of access: definition and
relationship to consumer satisfaction. Med Care. 1981;19:127–40.
ey Words: ACCF/AHA Performance Measures y abdominal aortic
neurysm y ankle brachial index y peripheral arterial disease y
econdary prevention y supervised exercise.PPENDIX A. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES—ACCF/AHA/ACR/SCAI/SIR/
VM/SVN/SVS 2010 PERFORMANCE MEASURES FOR ADULTS WITH PERIPHERAL ARTERY DISEASE
Committee
Member Employer/Title Consultant Speaker
Ownership/
Partnership/
Principal Research
Institutional,
Organizational, or
Other Financial
Benefit
Expert
Witness
effrey W.
Olin
(Chair)
Mt. Sinai School of
Medicine/Director,
Vascular Medicine
Program
● Bristol-Myers
Squibb/Sanofi
● Genzyme
● Schering-Plough
● Takeda
None None ● Genzyme
● Sanofi
None ● Cleveland
Clinic
Foundation*
● Johnson &
Johnson
avid E.
Allie
Cardiovascular Institute
of the South—
Lafayette/Chief of
Cardiothoracic and
Endovascular Surgery
● ev3*
● Flowmedica*
● Spectranetics*
● Toshiba/Bracco*
● Spectranetics None None None None
ichael
Belkin
Brigham and Women’s
Hospital, Harvard
Medical School/
Vascular Surgery
Fellowship Program
Director
● Aastrom
Biosciences, Inc.
● AGA Medical
None Merck None None None
obert O.
Bonow
Northwestern University
Feinberg School of
Medicine/Goldberg
Distinguished
Professor; Chief,
Division of Cardiology
None ● Edwards
Lifesciences*
None None None None
onald E.
Casey
Atlantic Health/Vice
President, Quality
and Chief Medical
Officer
None None None None None None
ark A.
Creager
Brigham and Women’s
Hospital
Cardiovascular
Division/Professor of
Medicine (Cardiology)
● ActivBiotics
● Biomarin
● Genzyme
● Kos
Pharmacuticals
● Sanofi-Aventis
● Sigma Tau
● Bristol-Myers
Squibb
● Merck ● Sanofi-Aventis None None
homas C.
Gerber
Mayo College of
Medicine, Mayo
Clinic Division of
Cardiovascular
Diseases/Associate
Professor of
Medicine and
Radiology
None None None None None None
AM
J
C
E
L
P
2162 Olin et al. JACC Vol. 56, No. 25, 2010
Performance Measures for Adults With PAD December 14/21, 2010:2147–81Committee
Member Employer/Title Consultant Speaker
Ownership/
Partnership/
Principal Research
Institutional,
Organizational, or
Other Financial
Benefit
Expert
Witness
lan T.
Hirsch
University of Minnesota
School of Public
Health/Professor of
Epidemiology and
Community Health
● Kos
Pharmaceuticals
● Pifzer*
● Roche*
● Bristol-Myers
Squibb/Sanofi-
Aventis
None ● Abbott Vascular
● AstraZeneca
● Bristol-Myers
Squibb/Sanofi-
Aventis
● Kos
Pharmaceuticals*
● Omron
● PreMD
● SonoSite
None None
ichael R.
Jaff
Massachusetts General
Hospital/Director,
Vascular Diagnostic
Lab
● Abbott Vascular
● Arsenal Medical
● Atheromed
● Bacchus Vascular
● Baxter Healthcare
● Boston Scientific
● Cortis
● FlexStent
● HCRI*
● Hypermed
● I.C. Sciences
● Medical
Simulation
Corporation
● Medtronic
● Micell
● Nexeon
MedSystems
● Pathway Medical
● Proteon
● Takeda
Pharmaceuticals
None None ● Access Closire
● Icon
Interventional
● Sadra Medical
● Setagon
● Square One
● Vascular
Therapies
● VIVA Physicians,
Inc.*
None
ohn A.
Kaufman
Dotter Interventional
Institute Oregon
Health and Science
University/Professor
of Radiology
None None None None None None
urtis A.
Lewis
The Grady Health
System/Chief of
Staff and Sr. Vice
President of Medical
Affairs
None None None None None None
dward T.
Martin
Oklahoma Heart
Institute/Director,
Cardiovascular MRI
Center
● Astellas
● Siemens
● GE
Healthcare*
None ● Siemens ● Astellas
● Siemens
None
ouis G.
Martin
Emory University
School of Medicine/
Professor,
Department of
Radiology
None None None None None None
eter
Sheehan
Mount Sinai School of
Medicine/Senior
Faculty
None ● Bristol-Myers
Squibb/Sanofi*
● Edwards
Lifesciences*
● FoxHollow*
None ● Genzyme*
● Nissan*
None None
KD
C
Z
T
u
a
i
f
A
S
H
R
2163JACC Vol. 56, No. 25, 2010 Olin et al.
December 14/21, 2010:2147–81 Performance Measures for Adults With PADCommittee
Member Employer/Title Consultant Speaker
Ownership/
Partnership/
Principal Research
Institutional,
Organizational, or
Other Financial
Benefit
Expert
Witness
erry J.
Stewart
Johns Hopkins
University School of
Medicine Johns
Hopkins Bayview
Medical Center/
Professor of
Medicine and
Director, Clinical and
Research Exercise
Physiology
None None None None None None
iane Treat-
Jacobson
University of Minnesota
School of Nursing/
Assistant Professor
● Kos
Pharmacuticals*
● Bristol-Myers
Squibb/Sanofi-
Aventis
None ● National Heart,
Lung, and Blood
Institute*
None None
hristopher
J. White
Ochsner Clinic
Foundation/Chairman,
Department of
Cardiology
None ● Baxter
● Boston
Scientific
None None None None
hi-Jie
Zheng
Center for the
Application of
Research Discoveries
National Heart, Lung
and Blood Institute/
Senior Medical
Epidemiologist
None None None None None None
his table represents the relationships of committee members with industry and other entities that were reported by authors to be relevant to this document. These relationships were reviewed and
pdated in conjunction with all meetings and/or conference calls of the writing committee during the document-development process. The table does not necessarily reflect relationships with industry
t the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, if the
nterest represents ownership of $10 000 or more of the fair market value of the business entity. or if funds received by the person from the business entity exceed 5% of the person’s gross income
or the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted.
*Significant relationship.
PPENDIX B. PEER REVIEWER RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES—ACCF/AHA/ACR/SCAI/
IR/SVM/SVN/SVS 2010 PERFORMANCE MEASURES FOR ADULTS WITH PERIPHERAL ARTERY DISEASE
Reviewer Representation Consultant Speaker
Ownership/
Partnership/
Principal
Personal
Research
Institutional,
Organizational or
Other Financial
Benefit
Expert
Witness
erbert Aronow Official Reviewer—SVM ● Cordis
● Medtronic
● Bristol-Myers
Squibb/Sanofi-
Aventis
● Pfizer*
None None None None
obert M.
Bersin
Official Reviewer—SCAI ● Abbott Vascular*
● Boston Scientific*
● Bristol-Myers
Squibb
● Cordis
Endovascular*
● Daiichi Sankyo
● Eli Lilly
● ev3*
● Medtronic
Vascular
● Palmaz Scientific
● ReVascular
Therapeutics
● Sanofi-Aventis
● Vascular Solutions
● W.L. Gore*
● Boston
Scientific*
● Bristol-Myers
Squibb
● Cordis
Endovascular*
● Daiichi Sankyo
● Eli Lilly
● The Medicines
Co.
● Sanofi-Aventis
● Boston
Scientific*
● Cordis
Endovascular*
None None None
AG
B
D
S
F
J
S
I
M
A
G
N
R
J
J
M
M
C
2164 Olin et al. JACC Vol. 56, No. 25, 2010
Performance Measures for Adults With PAD December 14/21, 2010:2147–81Reviewer Representation Consultant Speaker
Ownership/
Partnership/
Principal
Personal
Research
Institutional,
Organizational or
Other Financial
Benefit
Expert
Witness
lain T. Drooz Official Reviewer—SIR ● Possis Medical ● Peripheral
Angioplasty &
All that Jazz –
May 2007
None ● Invatec INTENSE
Trial DSMB
None None
ordon Fung Official Reviewer—ACCF
Board of Governors
None ● Abbott
Cardiovascular
● GlaxoSmithKline
None ● Roche
Pharmaceuticals
● AHA/LWW
● UCSF(Vice
Chair,
Committee on
Human
Research)
● UCSF School of
Medicine
(Director,
Clinical Faculty
Affairs)
None
ertrand Janne
d’Othee
Official Reviewer—ACR None None None None None None
ebra Kohlman-
Trigoboff
Official Reviewer—SVN None None None None None None
anjoy Kundu Official Reviewer—SIR None None None None None None
rank W.
LoGerfo
Official Reviewer—SVS None None None None None None
ames O.
Menzoian
Official Reviewer—SVS None None None None None None
anjay Misra Official Reviewer—AHA None None None ● National Center
for Research
Resources (part
of NIH)*
None None
ssam Moussa Official Reviewer—SCAI None None None None None None
artha J.
Radford
Official Reviewer—ACCF/
AHA Task Force on
Performance Measures
Lead Reviewer
None None None None None None
nne C. Roberts Official Reviewer—AHA
and ACR
None None None None ● ACR Board of
Chancellors
None
eorge P.
Rodgers
Official Reviewer—ACCF
Board of Trustees
● United Health None ● Biophysical* None ● Paragon Health ● For defendent
(injury on
treadmill)
akela Cook Organizational Reviewer—
NHLBI
None None None None None None
icardo C. Cury Organizational Reviewer—
SCCT
● Astellas Pharma ● Siemens None ● Astellas
Pharma*
● Pfizer Inc.*
● SCCT Board
Member
None
ames M.
Galloway
Organizational Reviewer—
ADA
None None None None None None
erry Goldstone Organizational Reviewer—
PAD Coalition
● Vascutek, a
TERUMO company
None None None None None
arjorie L. King Organizational Reviewer—
AACVPR
None None None None None None
. Sue Kirkman Organizational Reviewer—
ADA
None None None None None None
hristopher
Kramer
Organizational Reviewer—
SAIP
● Siemens Medical
Solutions
● Merck
● Schering-
Plough
None ● Astellas*
● GlaxoSmithKline*
● Siemens Medical
Solutions*
None None
JK
D
C
F
R
A
S
E
K
H
W
L
D
R
2165JACC Vol. 56, No. 25, 2010 Olin et al.
December 14/21, 2010:2147–81 Performance Measures for Adults With PADReviewer Representation Consultant Speaker
Ownership/
Partnership/
Principal
Personal
Research
Institutional,
Organizational or
Other Financial
Benefit
Expert
Witness
ohn R. Lesser Organizational Reviewer—
SCCT
● Vital Images ● Siemens
Medical
Solutions
None None None None
eith Michl Organizational Reviewer—
ACP
None None None None None None
iane Reid Organizational Reviewer—
NHLBI
None None None None None None
arolyn
Robinson
Organizational Reviewer—
PAD Coalition
None None None None None None
rank Rybicki Organizational Reviewer—
SCMR
None ● Vital Images None ● Bracco
Diagnostics
● Toshiba Medical
Systems
None None
ay Squires Organizational Reviewer—
AACVPR
None None None None None None
llen Taylor Organizational Reviewer—
SAIP
None ● Abbott* None ● Abbott None None
teven D. Wolff Organizational Reviewer—
SCMR
● GE Healthcare* None ● NeoCoil,
LLC
● NeoSoft,
LLC
None None None
lizabeth
Delong
Content Reviewer—ACCF/
AHA Task Force on
Performance Measures
None None None None None None
athleen Grady Content Reviewer—ACCF/
AHA Task Force on
Performance Measures
None None None None None None
itinger Gurm Content Reviewer—ACCF
Peripheral Vascular
Disease Committee
● Icon
Interventional
Systems
None None ● Blue Cross Blue
Shield of
Michigan*
None None
illiam Hiatt Content Reviewer—
Individual
None None None ● Bristol-Myers
Squibb/Sanofi-
Aventis*
● Otsuka Japan*
None None
oren F.
Hiratzka
Content Reviewer—ACC/
AHA 2005 PAD Clinical
Practice Guideline
Writing Committee
None ● AHA None None None None
avid J.
Malenka
Content Reviewer—ACCF/
AHA/ACR/SCAI/SIR/
STS/SVM/SVN/SVS
PAVD Data Standards
Writing Committee
None None None ● Abbott Vascular*
● St. Jude Medical
Foundation*
None None
ichard Milani Content Reviewer—
Individual
None ● Astra-Zeneca
● Bristol-Myers
Squibb*
● Pfizer
● Sanofi-Aventis
None None None ● For plaintiff
(suit alleging
owners of
boat-diving
company
failed to
provide timely
medical care
for a
passenger
who suffered
acute MI)
TT
a
i
f
l
b
v
S
2166 Olin et al. JACC Vol. 56, No. 25, 2010
Performance Measures for Adults With PAD December 14/21, 2010:2147–81Reviewer Representation Consultant Speaker
Ownership/
Partnership/
Principal
Personal
Research
Institutional,
Organizational or
Other Financial
Benefit
Expert
Witness
imothy Murphy Content Reviewer—
Individual
● Bristol-Myers
Squibb*
None None ● Abbott Vascular*
● Boston
Scientific*
● Cordis/Johnson
& Johnson*
● Otsuka
Pharmaceuticals*
None None
his table represents the relevant relationships with industry and other entities that were disclosed by reviewers at the time of peer review. It does not necessarily reflect relationships with industry
t the time of publication. A person is deemed to have a significant interest in a business if the interest represents ownership of 5% or more of the voting stock or share of the business entity, if the
nterest represents ownership of $10 000 or more of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of the person’s gross income
or the previous year. A relationship is considered to be modest if it is less than significant under the preceding definition. Relationships in this table are modest unless otherwise noted. Names are
isted in alphabetical order within each category of review. Participation in the peer review process does not imply endorsement of this document.
*Significant relationship.
ACC indicates American College of Cardiology; ACCF, American College of Cardiology Foundation; ACR, American College of Radiology; AHA, American Heart Association; DSMB, data safety monitoring
oard; LWW, Lippincott, Williams, & Wilkins; NHLBI, National, Heart, Lung, and Blood Institute; NIH, National Institutes of Health; PAD, peripheral arterial disease; PAVD, peripheral atherosclerotic
ascular disease; SCAI, Society for Cardiac Angiography and Interventions; SCCT, Society of Cardiovascular Computed Tomography; SIR, Society of Interventional Radiology; STS, Society of Thoracic
urgeons; SVM, Society for Vascular Medicine; SVN, Society of Vascular Nursing; SVS, Society for Vascular Surgery; and UCSF, University of California, San Francisco.
A
P
N
D
P
S
T
c
A
C
I
d
T
l
T
R
R
A
●
●
●
●
T
w
P
W
P
P



A
t
2167JACC Vol. 56, No. 25, 2010 Olin et al.
December 14/21, 2010:2147–81 Performance Measures for Adults With PADPPENDIX C. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 PERFORMANCE MEASURES FOR ADULTS WITH
ERIPHERAL ARTERY DISEASE PERFORMANCE MEASUREMENT SET SPECIFICATIONS
1. ABI
Measurement of ABI in patients at risk for PAD
umerator Patients in whom measurement and numerical results of an ABI* are documented at least once in the last 5 y.
enominator All patients:
 Age 18 y with walking impairment or claudication or lower extremity nonhealing wounds OR
 Age 50–69 y with a history of smoking or diabetes OR
 Age 70 y
Exceptions:
 Patients with known atherosclerosis in any other location (e.g., coronary, carotid, or renal artery disease).
 Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant for not performing an ABI
(e.g., amputation or limited life expectancy).
eriod of Assessment 5-y measurement period
ources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
he ABI is a very specific and sensitive measure for the detection of PAD. It can be performed in the office setting and predicts morbidity and mortality. PAD is
onsidered a CHD risk equivalent, and documentation of PAD changes the management of risk factors such as hypertension and dyslipidemia.
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
ndividuals with asymptomatic lower extremity PAD should be identified by examination and/or measurement of the ABI so that therapeutic interventions known to
iminish their increased risk of myocardial infarction, stroke, and death may be offered. (Level of Evidence: B)
he resting ABI should be used to establish the lower extremity PAD diagnosis in patients with suspected lower extremity PAD, defined as individuals with exertional
eg symptoms, with nonhealing wounds, who are 70 years or older or who are 50 years or older with a history of smoking or diabetes. (Level of Evidence: C)
ASC-II (40)
ecommendation 12
ecommendations for ABI screening to detect peripheral arterial disease in the individual patient.
n ABI should be measured in:
All patients who have exertional leg symptoms [B].
All patients age 50 to 69 y and who have a cardiovascular risk factor (particularly diabetes or smoking) [B].
All patients age 70 y regardless of risk factor status [B].
All patients with a Framingham Risk Score 10%–20% [C].
Attribution/Aggregation
his measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation” (clinician versus practice)
ill depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
er patient:
hether an ABI was performed at least once in the last 5 y.
er patient population:
ercentage of patients for whom ABI was performed at least once in the last 5 y.
Challenges to Implementation
Lack of uniform reimbursement for ABI performed according to evidence-based guidelines.
Lack of equipment to perform this measurement in the physician’s office.
Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
BI indicates ankle-brachial index; CHD, coronary heart disease; and PAD, peripheral artery disease.
*ABI is the ratio of the systolic ankle arterial pressure to the systolic brachial arterial pressure. The higher of the brachial pressures is used as the denominator for both right and left ratios, and
he higher of the 2 ankle pressures (posterior tibial or dorsalis pedis) is used as the numerator for each leg.
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Drug therapy for lowering LDL-C in patients with PAD
umerator Patients who
 Were prescribed a statin and whose LDL-C is 100 mg/dL OR
 Were prescribed a statin at maximal dose* OR
 Whose LDL-C is 100 mg/dL without a statin OR
 Whose LDL-C 100 mg/dL and who had a medical or patient reason that a statin at maximal dose* was not prescribed
documented by a physician, advanced practice nurse, or physician assistant.
enominator All patients age 18 y with PAD.
PAD is defined as the presence of 1 or more of the following:
 Claudication
 Critical limb ischemia (ischemic rest pain, nonhealing ischemic ulcers, gangrene)
 History of vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities
 Amputation for critical limb ischemia
 Abnormal noninvasive test (e.g., ankle brachial index, ultrasound, magnetic resonance, or computed tomography imaging
demonstrating stenosis in any peripheral artery; i.e., aorta, iliac, femoral, popliteal, tibial, peroneal).
Exceptions:
None
eriod of Assessment 1-y measurement period
ources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
reatment of dyslipidemia reduces the risk of adverse cardiovascular events in patients with atherosclerosis. Cholesterol-lowering therapy with an HMG coenzyme-A
eductase inhibitor (statin) reduces the risk of myocardial infarction, stroke, and cardiovascular death in patients with coronary artery disease. In the Heart
rotection Study, statins reduced the risk of myocardial infarction, stroke, or cardiovascular death by 24% in patients with PAD (68). Despite the proven efficacy of
ffective lipid-lowering therapy in patients with PAD, these patients are undertreated when compared to patients with coronary artery disease.
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
reatment with a HMG coenzyme-A reductase inhibitor (statin) medication is indicated for all patients with PAD to achieve a target LDL-C level of 100 mg/dL.
Level of Evidence: B)
lass IIa
reatment with an HMG coenzyme-A reductase inhibitor (statin) medication to achieve a target LDL-C level of 70 mg/dL is reasonable for patients with lower
xtremity PAD at very high risk of ischemic events. (Level of Evidence: B)
HA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update (69)
or lipid management:
ssess fasting lipid profile in all patients, and within 24 hr of hospitalization for those with an acute cardiovascular or coronary event. For hospitalized patients,
nitiate lipid-lowering medication as recommended below before discharge according to the following schedule:
LDL-C should be 100 mg/dL (Class I, Level of Evidence: A), and
Further reduction of LDL-C to 70 mg/dL is reasonable. (Class IIa, Level of Evidence: A)
If baseline LDL-C is 100 mg/dL, initiate LDL-lowering drug therapy.† (Class I, Level of Evidence: A)
If on-treatment LDL-C is 100 mg/dL, intensify LDL-lowering drug therapy (may require LDL-lowering drug combination‡). (Class I, Level of Evidence: A).
Attribution/Aggregation
his measure should be reported by all primary care physicians or primary care practices and cardiovascular medicine physicians or cardiovascular medicine
ractices. The level of “aggregation” (clinician versus practice) will depend upon the availability of adequate sample sizes to provide stable estimates of
erformance.
Method of Reporting
er patient:
hether patient
Was prescribed a statin and had LDL-C 100 mg/dL OR
Was prescribed a statin at maximal dose* OR
Had LDL-C 100 mg/dL without a statin OR
Had LDL-C 100 mg/dL and had a medical or patient reason that a statin at maximal dose* was not prescribed documented by a physician,
advanced practice nurse, or physician assistant.
er patient population:
ercentage of all patients who
Were prescribed a statin and had LDL-C 100 mg/dL OR
Were prescribed a statin at maximal dose* OR
Had LDL-C 100 mg/dL without a statin OR
Had LDL-C 100 mg/dL and had a medical or patient reason that a statin at maximal dose* was not prescribed documented by a physician,
advanced practice nurse, or physician assistant.
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ample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
DL-C indicates low-density lipoprotein cholesterol; PAD, peripheral artery disease; and HMG, hydroxymethyl glutaryl.
*Maximal dosing for currently available statins:
 Atorvastatin80 mg/d
 Fluvastatin80 mg/d
 Lovastatin80 mg/d
 Pravastatin80 mg/d
 Rosuvastatin40 mg/d
 Simvastatin80 mg/d
†When LDL-lowering medications are used, obtain at least a 30% to 40% reduction in LDL-C levels. If LDL-C 70 mg/dL is the chosen target, consider drug titration to achieve this level, to minimize
ide effects and cost. When LDL-C 70 mg/dL is not achievable because of high baseline LDL-C levels, it generally is possible to achieve reductions of 50% in LDL-C levels by either statins or
DL-C–lowering drug combinations.
‡Standard dose of statin with ezetimibe, bile acid sequestrate, or niacin.
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Smoking-cessation intervention for active smoking in patients with PAD
umerator Patients identified as tobacco users who have received cessation intervention.
Cessation intervention may include smoking-cessation counseling (e.g., verbal advice to quit, referral to smoking-cessation
program or counselor) and/or pharmacologic therapy.* The type of intervention should be explicitly captured.
enominator All patients age 18 y at the start of the measurement period with PAD who are identified as tobacco users.
PAD is defined as the presence of 1 or more of the following:
 Claudication
 Critical limb ischemia (ischemic rest pain, nonhealing ischemic ulcers, gangrene)
 History of vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities
 Amputation for critical limb ischemia
 Abnormal noninvasive test (e.g., ankle brachial index, ultrasound, magnetic resonance, or computed tomography imaging
demonstrating stenosis in any peripheral artery; i.e., aorta, iliac, femoral, popliteal, tibial, peroneal).
Exceptions:
None
eriod of Assessment 2-y measurement period
ources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
obacco smoking is the most potent modifiable risk factor for development of PAD. Continued use of tobacco affects disease progression and graft patency.
moking status should be assessed at each encounter: patients should be strongly advised to quit, and resources to assist in quitting should be offered.
The 6 A factors should be included: ask, assess, advise, assure, arrange [a follow-up], and applaud).
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
ndividuals with lower extremity PAD who smoke cigarettes or use other forms of tobacco should be advised by each of their clinicians to stop smoking and should be
ffered comprehensive smoking-cessation interventions, including behavior modification therapy, nicotine replacement therapy, or bupropion. (Level of Evidence: B)*
Attribution/Aggregation
his measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation” (clinician versus practice)
ill depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
er patient:
hether the PAD patient identified as a tobacco user, received cessation intervention, and the type of cessation intervention that was provided as documented in
he medical records.
er patient population:
ercentage of PAD patients identified as tobacco users who received cessation intervention and a breakdown of the type of cessation intervention that was provided
s documented in the medical record.
Challenges to Implementation
Lack of documentation or consistency of description of interventions in medical record.
Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
AD indicates peripheral artery disease.
*Recent evidence supports the use of varenicline as an adjunct therapy for smoking cessation. For purposes of this measure, use of varenicline, nicotine replacement therapy, or bupropion should
ll be considered pharmacologic therapy for smoking cessation.
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Antiplatelet therapy to reduce the risk of myocardial infarction, stroke, or vascular death in patients with a history of symptomatic PAD
umerator Patients who were prescribed an antiplatelet agent (aspirin or clopidogrel)
enominator All patients age 18 y with a history of symptomatic PAD.
History of symptomatic PAD is defined as the presence of the following:
 Claudication OR
 Critical limb ischemia (ischemic rest pain, nonhealing ischemic ulcers, gangrene) OR
 History of vascular reconstruction, bypass surgery, or percutaneous intervention to the extremities OR
 Amputation for critical limb ischemia.
Exceptions:
 Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant for not prescribing an
antiplatelet agent (e.g., allergy or intolerance to both aspirin and clopidogrel, risk of bleeding, noncompliance, use of
warfarin, or other medical reason).
 Documentation of patient reason(s) for not prescribing an antiplatelet agent (e.g., patient refusal).
eriod of Assessment 1-y measurement period
ources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
dministration of antiplatelet agents to patients with symptomatic atherosclerotic lower extremity PAD is well documented to reduce the risk of
yocardial infarction, stroke, or vascular death.
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
. Antiplatelet therapy is indicated to reduce the risk of myocardial infarction, stroke, or vascular death in individuals with atherosclerotic lower extremity PAD.
(Level of Evidence: A)
. Aspirin, in daily doses of 75 to 325 mg, is recommended as safe and effective antiplatelet therapy to reduce the risk of myocardial infarction, stroke, or
vascular death in individuals with atherosclerotic lower extremity PAD. (Level of Evidence: A)
. Clopidogrel (75 mg/d) is recommended as an effective alternative antiplatelet therapy to aspirin to reduce the risk of myocardial infarction, stroke, or
vascular death in individuals with atherosclerotic lower extremity PAD. (Level of Evidence: B)
Attribution/Aggregation
his measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation” (clinician versus practice)
ill depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
er patient:
hether a patient with a history of symptomatic PAD was prescribed aspirin or clopidogrel.
er patient population:
ercentage of all patients with a history of symptomatic PAD who were prescribed aspirin or clopidogrel.
Challenges to Implementation
ample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
AD indicates peripheral artery disease.
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Supervised exercise training for patients with intermittent claudication
umerator Patients who were
 Offered a supervised exercise training program as an option (preferred) OR
 Given explicit written or verbal instructions for unsupervised exercise (acceptable alternative if no supervised program is
accessible*) AND had a medical, patient, or system reason documented by a physician, advanced practice nurse, or physician
assistant that they could not be offered a supervised program.
Note: Exercise training should be performed for a minimum of 30 to 45 min, at least 3 times/wk, for a minimum of 12 wks. (70)
enominator Patients age 18 y with intermittent claudication
Exceptions:
Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant that patient was not offered a
supervised exercise training program as an option, such as
 Critical limb ischemia (ischemic rest pain, nonhealing ischemic ulcers, gangrene)
 Unstable angina or recent myocardial infarction
 Decompensated heart failure
 Uncontrolled cardiac arrhythmias
 Severe or symptomatic valvular disease
 Other conditions that could be aggravated by exercise including, but not limited to, severe joint disease, uncontrolled
diabetes, uncontrolled hypertension, or severe pulmonary disease.
eriod of Assessment 1-y measurement period
ources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
supervised claudication exercise program is known to result in an increase in the speed, distance, and duration walked in a high fraction of candidates, with
ecreased claudication symptoms at each workload or distance. In addition, exercise programs achieve significant systemic risk-reduction benefits (lowered blood
ressure, improved glycemic control, and improved lipid profile). These functional and biochemical benefits accrue gradually and become evident over 4 to 8 wks
nd increase progressively over 12 wks. The biological mechanisms underlying the exercise improvements are complex, and there is inadequate evidence to
ttribute this functional benefit, as is often believed, to the growth of new collaterals (angiogenesis). Although the mechanism(s) by which exercise improves
alking is unknown, studies have suggested that 1 or more of the following may play a role: alterations in skeletal muscle metabolism, reduced inflammation,
mprovement in endothelial function and hemorheology, carnitine metabolism, or altered gait. Adverse events, although possible, are rare, and the risk can be
urther reduced with appropriate medical screening before starting a program.
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
ndividuals with intermittent claudication who are offered the option of endovascular or surgical therapies should be provided information regarding supervised
laudication exercise therapy and pharmacotherapy.
. A program of supervised exercise training is recommended as an initial treatment modality for patients with intermittent claudication. (Level of Evidence: A)
. Supervised exercise training should be performed for a minimum of 30 to 45 minutes, in sessions performed at least 3 times per week, for a minimum of
12 weeks. (Level of Evidence: A)
lass IIb
he usefulness of unsupervised exercise programs is not well established as an effective initial treatment modality for patients with intermittent claudication.
Level of Evidence: B)
ASC-II (40)
ecommendation 14
xercise therapy in intermittent claudication:
Supervised exercise should be made available as part of the initial treatment for all patients with peripheral arterial disease [A].
The most effective programs employ treadmill or track walking that is of sufficient intensity to bring on claudication, followed by rest, over the course of a
30 to 60-min session. Exercise sessions are typically conducted 3 times a week for 3 months [A].
merican College of Sports Medicine Guidelines for Exercise Testing and Prescription, 7th ed, 2006 (71)
nitial enrollment in a medically supervised program with ECG, heart rate, and BP monitoring is encouraged.
Attribution/Aggregation
his measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation” (clinician versus practice)
ill depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
er patient:
hether patient was offered the option of a supervised exercise program, if accessible, or given explicit instructions for an unsupervised program if a supervised
rogram is not accessible. Documentation should include whether a supervised exercise training program is available in the local community.
er patient population:
ercentage of patients who were offered the option of an exercise program either supervised, if accessible, or given explicit instructions for an unsupervised program if a
upervised program is not accessible. Documentation should include whether a supervised exercise training program is available in the local community.


*
o
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Locating information in the medical record.
Access to supervised exercise training records if the program is located at another facility.
Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
Inaccessible means that no program is available in the patient’s area, or is affordable by insurance or by pricing within the patient’s economic means, or will accommodate the patient’s work hours
r other fixed schedule barriers (72).
ND
P
S
I
p
R
r
m
S
f
T
D
A
C
L
p
D
i
T
t
P
W
P
P


A
2174 Olin et al. JACC Vol. 56, No. 25, 2010
Performance Measures for Adults With PAD December 14/21, 2010:2147–816. Lower Extremity Vein Bypass Graft Surveillance
ABI and Duplex ultrasound of lower extremity vein bypass site
umerator Patients who had an ABI and Duplex ultrasound of their infrainguinal vein bypass graft revascularization site at least once
during the 1-y measurement period.
enominator All patients age 40 y who have undergone arterial bypass with autologous vein graft surgery for infrainguinal
revascularization.
Exceptions:
 Patients with synthetic bypass grafts
 Patients with medical reason(s) documented by a physician, advanced practice nurse, or physician assistant for not
performing ABI and Duplex ultrasound (e.g., patients who have undergone major lower limb amputation remote from their
revascularization procedure)
 Documented patient reason(s) that ABI and Duplex ultrasound could not be performed (e.g., patient refusal)
eriod of Assessment 1-y measurement period
ources of Data Prospective flow sheet, retrospective medical record review, electronic medical record, vascular laboratory data reports
Rationale
nfrainguinal venous bypass grafts are at risk for developing stenoses, which, if unrecognized, may result in graft thrombosis. Once thrombosed, the secondary
atency rates of these grafts are poor. Performing physical examination and ABI testing are insufficient methods of determining whether a stenosis is present.
outine Duplex scan surveillance has been demonstrated to identify vein grafts at risk for failure. Although there is some conflict in the literature, identification and
evision of these grafts has been shown to improve long-term results. Synthetic grafts may also develop stenoses; however, graft thrombosis is relatively easily
anaged with surgical thrombectomy, and secondary patency rates are similar to those of primary assisted patency.
imilar data do not exist in infrainguinal endovascular intervention; however, if the revascularization was complex, and the challenges of restoring patency after
ailure of the intervention are great, it is intuitive that surveillance in a manner similar to that of infrainguinal venous bypass grafts be employed.
he durability of suprainguinal bypass grafts and endovascular interventions are superior to those of infrainguinal interventions, and given the challenges of
uplex ultrasound surveillance in iliac arteries, routine surveillance is not recommended.
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
ong-term patency of infrainguinal bypass grafts should be evaluated in a surveillance program, which should include an interval vascular history, resting ABIs,
hysical examination, and a Duplex ultrasound at regular intervals if a venous conduit has been used. (Level of Evidence: B)
uplex ultrasound is recommended for routine surveillance after femoral-popliteal and femoral-tibial-pedal bypass with a venous conduit. Minimum surveillance
ntervals are approximately 3, 6, and 12 months, and then yearly after graft placement. (Level of Evidence: A)
Attribution/Aggregation
his measure should be reported by vascular specialists or vascular specialist practices only. The level of “aggregation” (clinician versus practice) will depend upon
he availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
er patient:
hether ABI and Duplex ultrasound of the revascularization site was performed at least once during the measurement period.
er patient population:
ercentage of patients for whom ABI and Duplex ultrasound of the revascularization site was performed at least once during the measurement period.
Challenges to Implementation
This requires a vascular laboratory skilled in performance of lower extremity arterial Duplex ultrasonography, as well as having a method to schedule surveillance
testing of patients with infrainguinal lower extremity revascularization.
Sample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
BI indicates ankle-brachial index.
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December 14/21, 2010:2147–81 Performance Measures for Adults With PAD7. Monitoring of AAA
Monitoring of asymptomatic AAA between 4.0 and 5.4 cm in diameter
umerator Patients whose AAA diameter was measured at least once within the last year.
enominator All patients age 18 y and over with asymptomatic abdominal aortic aneurysm between 4.0 and 5.4 cm at the start of the
measurement period.
Exceptions:
 Patients with known symptomatic AAA
 Patients with AAA diameter 4.0 cm or 5.5 cm
 Patients who have had elective repair of their AAA
 Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant, for not measuring AAA
diameter, for example: Patients who are not candidates for AAA repair of any type due to comorbidities or surgical risk
(e.g., metastatic cancer, dementia, severe cardiopulmonary disease).
 Documented patient reason(s) for not measuring AAA diameter (e.g., patient refusal).
eriod of Assessment 1-y measurement period
ources of Data Electronic medical records, retrospective paper records, and prospective flow sheets
Rationale
neurysm size remains the single most important predictor not only for aneurysm rupture but also for death from other cardiovascular events. Prospective studies
ave indicated that small aneurysms (5.5 cm) have a low risk of rupture and may be safely monitored with annual or semiannual imaging.
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
. Patients with infrarenal or juxtarenal AAAs measuring 5.5 cm or larger should undergo repair to eliminate the risk of rupture. (Level of Evidence: B)
. Patients with infrarenal or juxtarenal AAAs measuring 4.0 to 5.4 cm should be monitored by ultrasound, computerized tomography imaging, or magnetic
resonance every 6 to 12 months to detect expansion. (Level of Evidence: A)
Attribution/Aggregation
his measure should be reported by all clinicians and/or practices managing patients with cardiovascular disease. The level of “aggregation”
clinician versus practice) will depend upon the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
er patient:
hether the patient’s abdominal aortic aneurysm diameter was measured.
er patient population:
ercentage of patients whose abdominal aortic aneurysm diameter was measured.
Challenges to Implementation
ample size may preclude reporting of reliable performance estimates, particularly at the clinician level.
AA indicates abdominal aortic aneurysms.
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Performance Measures for Adults With PAD December 14/21, 2010:2147–81T-1. Vascular Review of Systems for Lower Extremity PAD*
Medical or personal history of walking impairment, claudication, or ischemic rest pain and nonhealing wounds in patients at risk for lower extremity PAD
umerator All patients for whom a vascular review of systems is documented at least once in the last 2 years.
Vascular review of systems must include assessment of ALL of the following:
 Walking impairment or claudication
 Ischemic rest pain
 Lower extremity nonhealing wounds
enominator All patients age 18 y who are “at risk” for PAD.
At risk is defined as the presence of 1 or more of the following:
 Age 50 y, with diabetes and 1 or more other atherosclerosis risk factors (smoking, dyslipidemia, hypertension,
or hyperhomocysteinemia);
 Age 50–69 y, with a history of smoking or diabetes;
 Age 70 y;
 Known atherosclerosis in any other location (e.g., coronary, carotid, or renal artery disease).
Exceptions:
None
eriod of Assessment 2-y measurement period
ources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
here is a high prevalence (about 30%) of PAD in this “at risk” population. Because the symptoms of PAD may be confused with arthritis, or simply aging, it is
dvisable to specifically ask about symptoms of claudication or critical limb ischemia.
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
ndividuals at risk for lower extremity PAD (see Section 2.1.1, Table 2) should undergo a vascular review of symptoms to assess walking impairment, claudication,
schemic rest pain, and/or the presence of nonhealing wounds. (Level of Evidence: C)
able 2 (Section 2.1.1) Individuals at Risk for Lower Extremity Peripheral Arterial Disease:
Age 50 y, with diabetes and one other atherosclerosis risk factor (smoking, dyslipidemia, hypertension, or hyperhomocysteinemia)
Age 50–69 y and history of smoking or diabetes
Age 70 y
Leg symptoms with exertion (suggestive of claudication) or ischemic rest pain
Abnormal lower extremity pulse examination
Known atherosclerotic coronary, carotid, or renal artery disease
history of walking impairment, claudication, ischemic rest pain, and/or nonhealing wounds is recommended as a required component of a standard ROS for
dults age 50 y who have atherosclerosis risk factors and for adults age 70 y. (Level of Evidence: C)
ASC-II
ecommendation 1.1 (40)
istory and physical examination in suspected PAD:
Individuals with risk factors for PAD, limb symptoms on exertion, or reduced limb function should undergo a vascular history to evaluate for symptoms of
claudication or other limb symptoms that limit walking ability [B].
Attribution/Aggregation
his measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation” (clinician versus practice)
ill depend on the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
er patient:
hether a vascular review of systems was recorded.
er patient population:
ercentage of all patients who had a vascular review of systems recorded.
Challenges to Implementation
Identifying the population “at risk” for PAD.
Sample sizes may preclude reporting of reliable performance estimates, particularly at the clinician level.
AD indicates peripheral artery disease.
*This measure has been designated for use in internal quality improvement programs only. It is not appropriate for any other use (e.g., pay for performance, physician ranking, or public reporting
rograms).
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December 14/21, 2010:2147–81 Performance Measures for Adults With PADT-2. PAD “At Risk” Population Pulse Examination*
Measurement of pulses in the lower extremities in patients at risk for PAD
umerator Patients in whom a lower extremity pulse examination was documented at least once in the last 2 years.
The pulse examination should include the femoral, popliteal, dorsalis pedis, and posterior tibial pulses.
enominator All patients age 18 y who are “at risk” for PAD.
At risk is defined as the presence of 1 or more of the following:
 Age 50 y, with diabetes and 1 or more other atherosclerosis risk factors (smoking, dyslipidemia, hypertension,
or hyperhomocysteinemia);
 Age 50–69 y, with a history of smoking or diabetes;
 Age 70 y;
 Walking impairment or claudication, ischemic rest pain, or lower extremity nonhealing wounds
 Known atherosclerosis in any other location (e.g., coronary, carotid, or renal artery disease).
Exceptions:
Medical reason(s) documented by a physician, advanced practice nurse, or physician assistant for not performing a lower
extremity pulse examination (e.g., amputation).
eriod of Assessment 2-y measurement period
ources of Data Prospective flow sheet, retrospective medical record review, electronic medical record
Rationale
xamination of the pulses is important to document the presence of peripheral artery disease, determine the location of obstruction, and detect the presence of
neurysms.
Clinical Recommendation(s)
CC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (12)
lass I
ndividuals at risk for lower extremity PAD (see Section 2.1.1, Table 2, of the full-text guidelines) should undergo comprehensive pulse examination and inspection
f the feet. (Level of Evidence: C)
able 2 (Section 2.1.1) Individuals at Risk for Lower Extremity Peripheral Arterial Disease:
Age 50 y, with diabetes and 1 other atherosclerosis risk factor (smoking, dyslipidemia, hypertension, or hyperhomocysteinemia)
Age 50–69 y and history of smoking or diabetes
Age 70 y
Leg symptoms with exertion (suggestive of claudication) or ischemic rest pain
Abnormal lower extremity pulse examination
Known atherosclerotic coronary, carotid, or renal artery disease
ASC-II
ecommendation 1.1 (40)
istory and physical examination in suspected PAD:
Patients at risk for PAD or patients with reduced limb function should also have a vascular examination evaluating peripheral pulses [B].
Attribution/Aggregation
his measure should be reported by all clinicians or practices managing patients with cardiovascular disease. The level of “aggregation” (clinician versus practice)
ill depend on the availability of adequate sample sizes to provide stable estimates of performance.
Method of Reporting
er patient:
hether a lower extremity pulse examination was performed.
er patient population:
ercentage of patients for whom a lower extremity pulse examination was performed.
Challenges to Implementation
dentifying the population “at risk” for PAD.
ample sizes may preclude reporting of reliable performance estimates, particularly at the clinician level.
AD indicates peripheral artery disease.
*This measure has been designated for use in internal quality improvement programs only. It is not appropriate for any other use (e.g., pay for performance, physician ranking, or public reporting
rograms).
APPENDIX D. SAMPLE PERFORMANCE MEASURE SURVEY FORM AND EXCLUSION CRITERIA DEFINITIONS
SAMPLE SURVEY FORM
PERFORMANCE MEASURE SURVEY
Please see the definition for each of the criteria below in the attached Performance Measure Survey Guide.
Indicate your selection by marking X in the appropriate field
ACC/AHA PAD
GUIDELINE
RECOMMENDATIONS
A.
Insufficient
evidence
B.
Uninterpretable
C.
Not
actionable
D.
Unclear
patient
population
E.
Not
clinically
meaningful
F.
Uncertain
reliability
across
settings
G.
Uncertain
feasibility
due to data
collection
effort
H.
Uncertain
feasibility
due to cost
of data
collection
I.
Uncertain
data
collection
period
Other,
specify
Potential
measure?
Y/N/Other Comment
Recommendation
from guideline to
be considered as
potential measure*
*Example: The resting ABI should be used to establish the lower extremity PAD diagnosis in patients with suspected lower extremity PAD, defined as individuals with exertional leg symptoms, with nonhealing wounds, who are age 70 or who are age 50 y with a
history of smoking or diabetes. (Level of Evidence: C).
ABI indicates ankle-brachial index; PAD, peripheral artery disease.
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Potential Challenge to Implementation Considerations
seful in Improving Patient Outcomes
. Insufficient evidence: The scientific basis for the recommendation is not
well established.
Considering level of evidence, mark this as a potential challenge to
implementation if you believe it is inappropriate to consider as a potential
performance measure.
. Not interpretable: The results of the (potential) measure are not
interpretable by practitioners
This is your assessment of the degree to which a provider can clearly
understand what the results of a measure based on this recommendation
mean and can take action if necessary.
. Not actionable: The recommendation addresses an area that is not under
the practitioner’s control.
This is your assessment of the degree to which a provider is empowered and
can influence the activities of the healthcare system toward improvement.
easure Design
. Unclear patient population This is your assessment of whether the patient group to whom this
recommendation applies (denominator) can be explicitly defined using
criteria that are clinically meaningful.
. Not clinically meaningful The recommendation does not capture clinically meaningful aspects of care.
. Uncertain reliability across settings The recommendation is not likely to be applicable across organizations and
delivery settings.
easure Implementation
. Uncertain feasibility due to data collection effort: The data required to
measure successful implementation of recommendation cannot be obtained
with reasonable effort.
From your perspective, the required data can be typically abstracted from
patient charts or there are national registries or other databases readily
available.
. Uncertain feasibility due to cost of data collection: The data required to
measure successful implementation of recommendation cannot be obtained
at reasonable cost.
. Uncertain data collection period: The data required to measure successful
implementation of recommendation cannot be obtained within the period
allowed for data collection.
verall Assessment
0. Overall assessment: Considering your assessment of this recommendation
on all dimensions above, rate this recommendation for inclusion in the
ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS PAD Performance Measure set.
Consider a balance in the continuum of care. Consider overall purpose of the
measurement set and the intended user.
On the survey form enter:
YES: This recommendation should be considered for further development into
a performance measure and inclusion in the ACCF/AHA/ACR/SCAI/SIR/
SVM/SVN/SVS PAD Performance Measure set.
NO: This recommendation should not be considered for further development
into a performance measure or inclusion in the ACCF/AHA/ACR/SCAI/SIR/
SVM/SVN/SVS PAD Performance Measure set.
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Performance Measures for Adults With PAD December 14/21, 2010:2147–81PPENDIX E. SAMPLE PROSPECTIVE DATA COLLECTION FLOWSHEET
CCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS Peripheral Artery Disease Performance Measurement Set
isit Date: ______ /______ /______ Physician Evaluating Patient: ____________________________
. Demographics/Patient Information
atient Last Name:
_______________________
Patient First Name: ________________________ Patient Middle Name/Initial: _________________
ex: e Male
e Female
Date of Birth: ____ /____ /____ Age: _________ years
. History/Diagnoses (Check all that apply)
Peripheral Artery Disease (PAD) e Claudication e Optional: Hyperhomocysteinemia
Diabetes e Walking Impairment e Optional: Hypertension
Atherosclerosis other than PAD (coronary,
carotid, or renal artery disease)
e Lower Extremity Nonhealing Wounds e Optional: Dyslipidemia
e Critical limb ischemia (ischemic rest pain,
nonhealing ischemic ulcers, gangrene)
e Optional: Ischemic Rest Pain
Infrainguinal vein bypass graft revascularization
¡ If yes, and patient is age 40 y, also complete section 7 below
bdominal Aortic Aneurysm (AAA): e Yes e No
¡ Complete if patient has a history of AAA: e Elective repair of AAA performed
¡ Complete if no elective repair has been performed: Most recent AAA diameter: ____________cm Date diameter measured: ____ /____ /____
¡ Complete if AAA diameter not measured:
edical or patient reason(s) AAA diameter was not measured (MD, DO, APN or PA only): __________________________________________________
obacco Use: e Never smoked e Former smoker: Date Quit: ____ /_____ (month, if known/year) e Current Smoker
Complete if patient is a current smoker:
Advised to quit smoking e Referred for smoking-cessation counseling e Medication prescribed: ______________________
(e.g., bupropion, varenicline, nicotine patches, gum, or lozenges)
e Other ____________________________
. Laboratory Assessments
DL-Cholesterol ________mg/dL
. Medications (Current and Prescribed)
edication Allergy/Intolerance: e Aspirin e Clopidogrel e Statin Medications
Medication Category
Prescribed
Yes No
A Aspirin e e ¡ Complete if neither aspirin nor clopidogrel prescribed:
Clopidogrel e e Medical or patient reason(s) neither aspirin nor clopidogrel prescribed
(MD, DO, APN, or PA only): _________________________________
B Statin Medication e e ¡ If Yes, enter
name, dosage,
and frequency
of statin
medication
Statin Name Statin Dosage Statin Frequency
Complete if no statin medication prescribed:
edical or patient reason(s) statin not prescribed or reason statin could not be prescribed at maximal dosage*
MD, DO, APN, or PA only): ___________________________________
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. Optional: Lower Extremity Pulse Examination
omplete if patient is:
Age 50 y, with a history of diabetes and 1 or more of the following: smoking, dyslipidemia, hypertension, or hyperhomocysteinemia
R
Age 50–69 y, with a history of smoking or diabetes
R
Age 70 y
R
Has a history of walking impairment or claudication, ischemic rest pain, or lower extremity nonhealing wounds
R
Has known atherosclerosis in any other location (e.g., coronary, carotid, or renal artery disease).
ulse location Pulse examination
performed
¡ If yes, record Narrative or Numeric Assessment (e.g., present or absent, or
graded on scale [0  absent, 1diminished, 2normal, 3bounding])
Yes No
emoral e e
opliteal e e
orsalis pedis e e
osterior tibial e e
Complete if any of the pulses above was not examined:
edical reason(s) for not performing lower extremity pulse examination (MD, DO, APN, or PA only): ________________________________________________
. Ankle Brachial Index
omplete if patient is:
Age  18 y, with a history of walking impairment or claudication or lower extremity nonhealing wounds
R
Age 50–69 y, with a history diabetes or smoking
R
Age 70 y
nkle Brachial Index (ABI) performed ¡ If yes, enter ¡ Complete if no ABI performed:
Yes e No Numerical result:
(R) ________
(L) ________
Medical reason(s) for not performing an ABI (MD, DO, APN, or PA
only):___________________________________
. Other Diagnostic Tests (Revascularization Surveillance)
omplete if patient is age 40 y and has history of infrainguinal vein bypass graft revascularization or infrainguinal endovascular revascularization. (Optional for endovascular
evascularization)
uplex ultrasound of revascularization site performed ¡ Complete if no Duplex ultrasound performed:
Yes e No Medical or patient reason(s) for not performing Duplex ultrasound of revascularization site (MD, DO,
APN, or PA only): ______________________
BI of revascularization site performed ¡ Complete if no ABI performed:
Yes e No Medical or patient reason(s) for not performing ABI of revascularization site (MD, DO, APN, or PA
only):______________________
. Therapeutic Recommendations
omplete if patient has a history of claudication
atient offered a supervised exercise training program Yes No
e e
Complete if no supervised exercise program is accessible: e e
atient given explicit written or verbal instruction for unsupervised exercise
Complete if only written or verbal instructions given:
eason supervised exercise program could not be offered: ______________________
Complete if patient was not offered a supervised exercise training program or given explicit written or verbal instructions for unsupervised exercise:
edical reason(s) patient was not offered a supervised exercise training program or given explicit written or verbal instructions for unsupervised exercise
MD, DO, APN or PA only): __________________
Maximal dosing for currently available statins:
torvastatin 80 mg/d Pravastatin 80 mg/d
luvastatin 80 mg/d Rosuvastatin40 mg/d
ovastatin 80 mg/d Simvastatin 80 mg/d
